Athenex (ATNXQ) 10-K 2 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Feb. 28, 2020	Jun. 30, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	ATNX
Entity Registrant Name	ATHENEX, INC.
Entity Central Index Key	0001300699
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		81,627,093
Entity Public Float			$ 867
Entity Incorporation, State or Country Code	DE
Entity File Number	001-38112
Entity Tax Identification Number	43-1985966
Entity Address, Address Line One	1001 Main Street
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Buffalo
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14203
City Area Code	716
Local Phone Number	427-2950
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for its 2020 annual meeting of stockholders currently scheduled to be held June 5, 2020 are incorporated by reference into Part III hereof.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 127,674	$ 49,794
Short-term investments	33,139	57,629
Accounts receivable, net of chargebacks and other deductions of $14,394 and $13,101, respectively, and allowance for doubtful accounts of $124 and $9, respectively	16,689	12,951
Inventories	32,630	28,787
Prepaid expenses and other current assets	20,794	21,658
Total current assets	230,926	170,819
Property and equipment, net	23,153	11,447
Goodwill	38,513	37,495
Intangible assets, net	8,522	10,848
Operating lease right-of-use assets, net	8,818
Deferred income tax asset		486
Total assets	309,932	231,095
Current liabilities:
Accounts payable	23,331	12,997
Accrued expenses	44,307	37,718
Current portion of operating lease liabilities	3,010
Current portion of long-term debt	880	961
Total current liabilities	71,528	51,676
Long-term liabilities:
Long-term operating lease liabilities	7,620
Long-term debt and finance lease obligations	52,366	45,803
Other long-term liabilities	2,563	4,847
Total liabilities	134,077	102,326
Commitments and contingencies (Note 19)
Stockholders' equity:
Common stock, par value $0.001 per share, 250,000,000 shares authorized at December 31, 2019 and 2018; 83,231,063 and 68,668,986 shares issued at December 31, 2019 and 2018, respectively; 81,558,143 and 66,996,066 shares outstanding at December 31, 2019 and 2018, respectively	83	69
Additional paid-in capital	763,648	591,064
Accumulated other comprehensive loss	(635)	(656)
Accumulated deficit	(567,465)	(443,716)
Less: treasury stock, at cost; 1,672,920 shares at December 31, 2019 and 2018	(7,406)	(7,406)
Total Athenex, Inc. stockholders' equity	188,225	139,355
Non-controlling interests	(12,370)	(10,586)
Total stockholders' equity	175,855	128,769
Total liabilities and stockholders' equity	$ 309,932	$ 231,095

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Accounts receivable, chargebacks and other deductions (in dollars)	$ 14,394	$ 13,101
Allowance for doubtful accounts (in dollars)	$ 124	$ 9
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	83,231,063	68,668,986
Common Stock, shares outstanding	81,558,143	66,996,066
Treasury stock, shares	1,672,920	1,672,920

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Total revenue	$ 101,229	$ 89,100	$ 38,043
Costs and operating expenses:
Cost of sales	69,619	47,005	25,122
Research and development expenses	84,393	119,905	76,797
Selling, general, and administrative expenses	66,749	49,008	46,112
Total costs and operating expenses	220,761	215,918	148,031
Operating loss	(119,532)	(126,818)	(109,988)
Interest income	(1,881)	(1,788)	(367)
Interest expense	6,954	3,581	6,279
Loss on derivative liability			15,411
Loss before income tax expense	(124,605)	(128,611)	(131,311)
Income tax expense	928	100	85
Net loss	(125,533)	(128,711)	(131,396)
Less: net loss attributable to non-controlling interests	(1,784)	(11,271)	(226)
Net loss attributable to Athenex, Inc.	(123,749)	(117,440)	(131,170)
Unrealized (loss) gain on investment, net of income taxes	(97)	15	(26)
Foreign currency translation adjustment, net of income taxes	118	(525)	1,184
Comprehensive loss	$ (123,728)	$ (117,950)	$ (130,012)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (Note 14)	$ (1.67)	$ (1.82)	$ (2.63)
Weighted-average shares used in computing net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (Note 14)	74,054,261	64,590,270	49,960,925
Product Sales, Net
Revenue:
Total revenue	$ 80,535	$ 56,394	$ 36,106
License and Other Revenue
Revenue:
Total revenue	$ 20,694	$ 32,706	$ 1,937

Consolidated Statements of Stoc

Consolidated Statements of Stockholders Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Total Athenex, Inc. Stockholders' Equity	Non-Controlling Interests
Beginning balance at Dec. 31, 2016	$ 34,669	$ 42	$ 237,581	$ (195,106)	$ (1,304)	$ (7,406)	$ 33,807	$ 862
Beginning balance, shares at Dec. 31, 2016		42,342,706				(1,656,920)
Sale of common stock	64,194	$ 7	64,187				64,194
Sale of common stock, shares		6,900,000
Conversion of bonds	98,929	$ 9	98,920				98,929
Conversion of bonds, shares		8,522,728
Stock-based compensation cost	12,431		12,431				12,431
Stock-based compensation cost, shares		400,000
Research and development licensing fee satisfied with stock	6,250	$ 1	6,249				6,250
Research and development licensing fee satisfied with stock, shares		568,182
Vesting of restricted stock	2,160		2,160				2,160
Vesting of restricted stock, shares		421,982
Stock options and warrants exercised	2,278	$ 1	2,277				2,278
Stock options and warrants exercised, shares		738,764
Repurchase of common stock, shares						(16,000)
Non-controlling interests	49							49
Net loss	(131,396)			(131,170)			(131,170)	(226)
Other comprehensive income (loss), net of tax	1,158				1,158		1,158
Ending balance at Dec. 31, 2017	90,722	$ 60	423,805	(326,276)	(146)	$ (7,406)	90,037	685
Ending balance, shares at Dec. 31, 2017		59,894,362				(1,672,920)
Sale of common stock	117,616	$ 7	117,609				117,616
Sale of common stock, shares		7,486,261
Issuance of warrant	3,140		3,140				3,140
Stock-based compensation cost	10,003		10,003				10,003
Research and development licensing fee satisfied with stock	31,545		31,545				31,545
Research and development licensing fee satisfied with stock, shares		375,133
Vesting of restricted stock	1,008	$ 1	1,007				1,008
Vesting of restricted stock, shares		240,000
Stock options and warrants exercised	3,956	$ 1	3,955				3,956
Stock options and warrants exercised, shares		673,230
Net loss	(128,711)			(117,440)			(117,440)	(11,271)
Other comprehensive income (loss), net of tax	(510)				(510)		(510)
Ending balance at Dec. 31, 2018	128,769	$ 69	591,064	(443,716)	(656)	$ (7,406)	139,355	(10,586)
Ending balance, shares at Dec. 31, 2018		68,668,986				(1,672,920)
Sale of common stock	159,977	$ 14	159,963				159,977
Sale of common stock, shares		14,006,575
Equity consideration in connection with acquisition	748		748				748
Stock-based compensation cost	8,219		8,219				8,219
Restricted stock expense	1,671		1,671				1,671
Restricted stock expense, shares		223,723
Stock options exercised	$ 1,983		1,983				1,983
Stock options exercised, shares	331,779	331,779
Net loss	$ (125,533)			(123,749)			(123,749)	(1,784)
Other comprehensive income (loss), net of tax	21				21		21
Ending balance at Dec. 31, 2019	$ 175,855	$ 83	$ 763,648	$ (567,465)	$ (635)	$ (7,406)	$ 188,225	$ (12,370)
Ending balance, shares at Dec. 31, 2019		83,231,063				(1,672,920)

Consolidated Statements of St_2

Consolidated Statements of Stockholders Equity (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement Of Stockholders Equity [Abstract]
Stock issuance costs and discounts		$ 5,518	$ 11,706
Stock issuance costs	$ 1,103

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net loss	$ (125,533)	$ (128,711)	$ (131,396)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,817	3,269	3,673
Stock-based compensation expense	9,885	11,011	14,591
Loss on derivative liability			15,411
Amortization of debt discount	1,026	514	3,349
Deferred rent expense		262	856
Net loss on disposal of assets and impairment charges	232	236	80
Research and development license fees settled with convertible bond and stock		31,545	13,250
Interest incurred on converted bonds			2,759
Deferred income taxes	486	(365)	(327)
Changes in operating assets and liabilities, net of effect of acquisition:
Receivables, net	(3,738)	(4,483)	(5,691)
Prepaid expenses and other assets	864	(13,966)	(4,537)
Inventories	(3,844)	(12,226)	(12,321)
Accounts payable and accrued expenses	19,345	3,527	18,791
Net cash used in operating activities	(97,460)	(109,387)	(81,512)
Cash flows from investing activities:
Purchase of property and equipment	(13,572)	(3,321)	(5,440)
Receipts of refundable deposit			110
Payments for licenses	(4,175)	(110)	(1,550)
Acquisition activity	853
Purchases of short-term investments	(74,697)	(113,259)	(55,282)
Sale of short-term investments	99,090	67,727	52,144
Net cash provided by (used in) investing activities	7,499	(48,963)	(10,018)
Cash flows from financing activities:
Proceeds from sale of stock	161,080	123,134	75,900
Proceeds from issuance of convertible bonds			30,000
Proceeds from issuance of debt	6,464	50,000
Costs incurred related to the sale of stock	(1,103)	(5,518)	(10,168)
Costs incurred related to the issuance of debt		(1,993)
Proceeds from exercise of stock options	1,983	3,956	2,278
Investment from non-controlling interest			49
Repayment of finance lease obligations and long-term debt	(972)	(544)	(1,163)
Net cash provided by financing activities	167,452	169,035	96,896
Net increase in cash and cash equivalents	77,491	10,685	5,366
Cash and cash equivalents, beginning of period	49,794	39,284	33,125
Effect of exchange rate changes on cash and cash equivalents	389	(175)	793
Cash and cash equivalents, end of period	127,674	49,794	39,284
Supplemental cash flow disclosures
Interest paid	4,925	2,977	109
Income taxes paid	448	464	244
Non-cash investing and financing activities:
Accrued purchases of property and equipment	483	340	156
Cost of equity raise in accounts payable and accrued expenses			188
Convertible bond issued in lieu of licensing cash payment			7,000
Common stock issued in lieu of licensing cash payment		31,545	6,250
Common stock issued upon the conversion of bonds and derivative liability			98,929
Property and equipment financed under capital and finance leases			$ 688
Accrued purchases of licenses		$ 4,175
Equity consideration in connection with acquisition	$ 748

Company and Nature of Business

Company and Nature of Business	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Company and Nature of Business	1. Description of Business Athenex, Inc. (the “Company” or “Athenex”), originally under the name Kinex Pharmaceuticals LLC (“Kinex”), formed in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015. Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The Company’s current clinical pipeline is derived from Orascovery, Src Kinase Inhibition, T-cell receptor-engineered T-cells (“TCR-T”), and Arginine Deprivation Therapy technology platforms. The Company has assembled a leadership team and has established global operations across the pharmaceutical value chain to execute its mission to become a global leader in bringing innovative cancer treatments to the market and improve health outcomes. The Company is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities. The Company also conducts commercial sales of specialty products through its wholly owned subsidiary, Athenex Pharmaceutical Division (“APD”), and 503B products through its wholly owned subsidiary, Athenex Pharma Solutions (“APS”). Initial Public Offering On June 13, 2017, the Company’s Registration Statement on Form S-1 (File No. 333-217928) relating to the initial public offering (“IPO”) of its common stock was declared effective by the Securities and Exchange Commission (“SEC”). Pursuant to such Registration Statement, the Company sold an aggregate of 6,900,000 shares of its common stock at a price of $11.00 per share for cash proceeds of $64.2 million, net of underwriting discounts and commissions of $6.1 million and offering costs of $5.6 million. On June 14, 2017, the day of the IPO, convertible bonds with an aggregate principal value of $68.0 million, and a carrying value of $55.8 million, were converted into 7,727,273 shares of common stock. The IPO closed on June 19, 2017. On September 29, 2017, the remaining convertible bond with a principal value of $7.0 million was converted into 795,455 shares of common stock, at a 20% discount from the IPO price of $11 per share. Follow-On Offering In January 2018, the Company completed an underwritten public offering of 4,300,000 shares of its common stock. The Company granted the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock. In February 2018, the underwriters partially exercised their option, purchasing an additional 465,000 shares of common stock. All shares were offered by the Company at a price of $15.25 per share. The aggregate net proceeds were $68.1 million, net of underwriting discounts and commissions and offering expenses of $4.6 million. Debt and Equity Offering On July 3, 2018, the Company closed a privately placed debt and equity financing deal with Perceptive Advisors LLC and its affiliates (“Perceptive”) for gross proceeds of $100.0 million and received aggregate net proceeds of $97.1 million, net of fees and offering expenses. The Company entered into a 5-year senior secured loan for $50.0 million of this financing and issued 2,679,528 shares of its common stock at a purchase price of $18.66 per share for the remaining $50.0 million. The loan matures on the fifth anniversary from the closing date and bears interest at a floating per annum rate equal to London Interbank Offering Rates (“LIBOR”) (with a floor of 2.0%) plus 9.0%. The Company is required to make monthly interest-only payments with a bullet payment of the principal at maturity. The loan agreement contains specified financial maintenance covenants. The Company was in compliance with such covenants as of December 31, 2019 and 2018. In connection with the loan agreement, the Company granted Perceptive a warrant for the purchase of 425,000 shares of common stock at a purchase price of $18.66 per share. This was accounted for as a detachable warrant at its fair value and is recorded as an increase to additional paid-in-capital on the consolidated statement of stockholders’ equity for the year ended December 31, 2018. A corresponding debt discount was recorded as a reduction of the related debt in the consolidated balance sheet as of December 31, 2018. Private Placements On May 7, 2019, the Company closed a private placement with Perceptive Life Sciences Master Fund, Ltd., Avoro Capital Advisors (formerly known as venBio Select Fund LLC), OrbiMed Partners Master Fund Limited and the Biotech Growth Trust PLC (combined known as OrbiMed), (collectively, the “Investors”), pursuant to which the Company sold an aggregate of 10 million shares of its common stock to the Investors at a purchase price of $10.00 per share for aggregate net proceeds of $99.9 million, net of offering expenses of approximately $0.1 million. These shares were subsequently registered with the Securities and Exchange Commission (“SEC”) on July 23, 2019. On December 9, 2019, the Company closed a private placement with a group of institutional investors, led by Kingdon Capital Management, LLC (collectively, the “Institutional Investors”), pursuant to which the Company sold an aggregate of 3,945,750 shares of its common stock to the Institutional Investors at a purchase price of $15.30 per share for aggregate net proceeds of $59.4 million, net of offering expenses of approximately $1.0 million. These shares were subsequently registered with the SEC on January 28, 2020. Going Concern These consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of the business. The Company’s recurring losses from operations and negative cash flows from operations have raised substantial doubt regarding its ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company has incurred operating losses and negative cash flows from operations since its inception and, as a result, as of December 31, 2019 and 2018 had an accumulated deficit of $567.5 million and $443.7 million, respectively. As of December 31, 2019 the Company had approximately $160.8 million of cash, cash equivalents, and short-term investments. The Company believes that the existing cash, cash equivalents, and short-term investments will be sufficient to fund current operating plans into the first quarter of 2021, but will not be sufficient to fund current operating plans through one year after the date that these consolidated financial statements are issued. The Company has based these estimates on assumptions that may prove to be wrong, and it could spend the available financial resources much faster than expected and need to raise additional funds sooner than anticipated. Operations have been funded primarily through the sale of common stock and, to a lesser extent, from convertible bond financing and grant funding. The Company will require significant additional funds to conduct clinical trials and to fund its commercialization operations. There can be no assurance, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company may be required to delay, modify, or terminate its research and development programs or reduce its planned commercialization efforts. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations, including additional public offerings; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, it will need to reevaluate future operating plans. In addition, the Company’s plans to raise additional funds are subject to market conditions which are outside of its control, and therefore cannot be deemed to be probable; as such, those plans do not alleviate substantial doubt about its ability to continue as a going concern. The Company has a senior secured loan agreement with Perceptive which contains various covenants. A breach of any of these covenants could result in a default. If a default under this loan agreement is not cured or waived, the default could result in the acceleration of debt, which could require the Company to repay the debt in full prior to the date it is otherwise due. If the Company defaults, the lender may seek repayment through the Company’s subsidiary guarantors or by executing on the security interest granted pursuant to the loan agreement. The Company is subject to a number of risks similar to other biopharmaceutical companies, including, but not limited to, the lack of available capital, possible failure of preclinical testing or clinical trials, inability to obtain marketing approval of product candidates, competitors developing new technological innovations, unsuccessful commercialization strategy and launch plans for its proprietary drug candidates, market acceptance of the Company’s products, and protection of proprietary technology. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate sufficient product revenue and might not, if ever, achieve profitability and positive cash flow.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, measurement of acquired assets and assumed liabilities in business combinations, allowance for doubtful accounts, inventory reserves, the valuation of the derivative liability, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates. Functional Currency Assets and liabilities of subsidiaries that prepare financial statements in currencies other than the U.S. dollar are translated using rates of exchange as of the balance sheet date and the statements of operations and comprehensive loss are translated at the average rates of exchange for each reporting period. The Company recorded a foreign currency translation loss in accumulated other comprehensive loss of $0.1 million for the year ended December 31, 2019, a loss of $0.5 million for the year ended December 31, 2018 and a gain of $1.2 million for the year ended December 31, 2017. Cash, Cash Equivalents, and Marketable Securities The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, money market accounts, as well as certificates of deposit. Funds held in foreign accounts that are subject to regulations governing transfers oversees are included within cash and cash equivalents. As of December 31, 2019 and 2018, the Company had $7.6 million and $3.2 million, respectively, at its Chinese subsidiaries, which were subject to Chinese funds transfer limitations. The Company generally does not enter into investments for trading or speculative purposes, rather to preserve its capital for the purpose of funding operations. Accounts Receivable, net Accounts receivable are recorded at the invoiced amount. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts, based upon a history of past write-offs, the age of the receivables, and current credit conditions. Inventories Inventories for clinical trials are stated at the lower of cost and net realizable value, with approximate cost being determined on a first-in-first-out basis. Active pharmaceutical ingredient (“API”) inventory is stated at the lower of cost and net realizable value, with approximate cost being determined on a weighted average basis. The Company provides inventory write-downs based on excess and obsolete inventories determined primarily by future demand forecasts. The write-down is measured as the difference between the cost of the inventory and market, based upon assumptions about future demand, and is charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. Property and Equipment, net Property and equipment are recorded at cost or acquisition date fair value in a business acquisition. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is recorded to general and administrative expense in the consolidated statements of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred. Estimated useful lives for property and equipment are as follows: Property and Equipment Estimated Useful Life Land Not depreciated Equipment 5 - 8 years Furniture and fixtures 5 years Computer hardware 3 years Leasehold improvements Lesser of estimated useful life or remaining lease term Construction in process Not depreciated Leases On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) The lease liabilities are determined as the present value of future fixed minimum lease payments. In determining the discount rate, the Company uses rates implicit in the lease, or if not readily available, the Company uses an estimated incremental borrowing rate based on yield trends in the biotechnology and healthcare industry and debt instruments held by the Company with stated interest rates. The Company uses the stated rate per lease agreement in determining the finance lease liabilities. The lease term is determined at the commencement date and considers whether it is reasonably certain that the Company will exercise renewal options or termination options. The lease liabilities and ROU asset are amortized over the term of the lease with operating lease expenses being recognized on a straight-line basis over the lease terms. The Company elected the practical expedients permitted under Topic 842, which allows it to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term leases. See Note 10— Debt and Lease Obligations. Prior period amounts continue to be reported in accordance with our historic accounting under previous lease guidance, ASC 840, Leases Topic 840 ( Topic 840 Recent Accounting Pronouncements Fair Value of Financial Instruments Financial instruments consist of cash and cash equivalents, short-term investments, marketable securities, an investment, accounts receivable, accounts payable, accrued liabilities, contingent consideration, and long-term debt. Cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, contingent consideration, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts. Business Acquisitions The Company accounts for acquired businesses using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Identifiable amortizing intangible assets are recorded on the consolidated balance sheet at fair value and amortized over their estimated useful lives. Acquisition-related costs are expensed as incurred. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Goodwill The Company tests goodwill for impairment annually on October 1 st Intangible Assets, net Intangible assets arising from a business acquisition are recognized at fair value as of the acquisition date. The Company amortizes intangible assets using the straight-line method. When the straight-line method of amortization is utilized, the estimated useful life of the intangible asset is shortened to assure the recognition of amortization expense corresponds with the expected cash flows. Other purchased intangibles, including certain licenses, are capitalized at cost and amortized on a straight-line basis over the license life, when a future economic benefit is probable and measurable. If a future economic benefit is not probable or measurable, the license costs are expensed as incurred within research and development expenses. Impairment of Long-Lived Assets The Company reviews the recoverability of its long-lived assets, excluding goodwill, when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the assets from the expected future cash flows (undiscounted and without interest expense) of the related operations. If these cash flows are less than the carrying value of such assets, an impairment loss for the difference between the estimated fair value and carrying value is recorded. Impairment charges of $0.2 million, $0.3 million and $0.1 million were recorded for the years ended December 31, 2019, 2018, and 2017 respectively. See Note 5— Goodwill and Intangible Assets, net Treasury Stock The Company records treasury stock activities at the cost of the acquired stock. The Company’s accounting policy upon the formal retirement of treasury stock is to deduct the par value from common stock and to reflect any excess of cost over par value as a reduction to additional paid-in capital (to the extent created by previous issuances of the stock) and then accumulated deficit. Revenue Recognition Effective January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”), Topic 606, “ Revenue from Contracts with Customers Revenue Recognition Research and Development Expenses Costs for research and development (“R&D”) of products, including payroll, contractor expenses, and supplies, are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the obligations are recorded when the milestone results are probable of being achieved. Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Changes in unrealized gains and losses on investments and foreign currency translation adjustments represent the differences between the Company’s net loss and comprehensive loss. Stock-Based Compensation Awards granted to employees The Company recognizes stock-based compensation based on the grant date fair value of stock options granted to employees, officers, and directors. The Company used the Black-Scholes option pricing model to calculate the grant date fair value of stock options. The Black-Scholes option pricing model requires inputs for risk-free interest rate, dividend yield, volatility, fair value of common stock, and expected lives of the stock options. The risk-free rate for periods within the expected life of the stock option is based on the U.S. Treasury yield curve in effect at the time of the grant. No dividend yield is used, consistent with the Company’s history. Expected volatility is based on historical volatilities of the stock prices of peer biopharmaceutical companies. The fair value of common stock is based on the quoted market price of the Company’s common stock on grant date. The Company uses the simplified method for determining the expected lives of stock options. The Company recognizes compensation expenses based on the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting period. Stock grants The Company grants common stock to key officers and directors and records the fair value of these grants, based on the fair value of the common stock on the grant date, as compensation expense throughout the requisite service period. Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax expense or benefit is the result of changes in the deferred income tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred income tax assets where, based upon the available evidence, management concludes that it is more-likely-than not that the deferred income tax assets will not be realized. In evaluating its ability to recover deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of the deferred income tax assets, the Company has recorded a valuation allowance against its deferred income tax assets. Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more likely than not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in income tax expense (benefit); however, the Company currently has no interest or penalties related to income taxes. Segment and Geographic Information The Company’s chief operating decision-maker, its Chief Executive Officer, reviews its operating results on an aggregate basis and at the operating segment level for purposes of allocating resources and evaluating financial performance. The Company has three business platforms which are the operating segments: (1) Oncology Innovation Platform, for the discovery and development of cancer supportive therapies, (2) Commercial Platform, the manufacturing and selling of commercial pharmaceutical products, and (3) Global Supply Chain Platform, the cGMP manufacturing and marketing of API, and clinical products. Each operating segment has a segment manager who is held accountable for operations and operating results. Accordingly, the Company operates in three reportable segments. Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit and invests in highly liquid U.S. treasury notes, commercial paper, and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility, and research and development facility in China, and therefore is subject to foreign currency fluctuation and regulatory uncertainties. Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, " Leases (Topic 842), The Company adopted the new lease standard on January 1, 2019 and used the effective date as the date of initial application. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company (1) to not reassess whether any expired or existing contracts are or contain leases, (2) to not reassess the lease classification for any expired or existing leases, and (3) to not reassess initial direct costs for any existing leases. The Company also elected the single component practical expedient, which requires the Company, by class of underlying asset, not to allocate the total consideration to the lease and nonlease components based on their relative stand-alone selling prices. This single component practical expedient requires the Company to account for the lease component and nonlease component(s) associated with that lease as a single component if (i) the timing and pattern of transfer of the lease component and the nonlease component(s) associated with it are the same and (ii) the lease component would be classified as an operating lease if it were accounted for separately. In preparation for adoption of the standard and to assess the ongoing impact of the standard, the Company implemented internal controls to enable the preparation of financial information. The standard had a significant impact on the consolidated balance sheet, with no significant impact on its consolidated statement of operations and comprehensive loss. On the adoption date, the Company recognized $9.8 million of operating lease ROU assets, $11.9 million of operating lease liabilities, and derecognized its existing deferred rent balance of $2.1 million. The new standard provides a number of optional practical expedients in transition. The Company has elected the package of practical expedients permitted under the transition guidance within the new standard, which allows the Company (1) to not reassess whether any expired or existing contracts are or contain leases, (2) to not reassess the lease classification for any expired or existing leases, and (3) to not reassess initial direct costs for any existing leases In preparation for adoption of the standard, the Company has implemented internal controls to enable the preparation of financial information. Further, the Company has made an accounting policy election to keep leases with an initial term of twelve months or less off the balance sheet. The Company recognizes those lease payments in the consolidated statement of operations and comprehensive loss over the lease term. See Note 10— Debt and Lease Obligations Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “ Measurement of Credit Losses on Financial Instruments”

Inventories

Inventories	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventories	3. Inventories consist of the following (in thousands): December 31, 2019 2018 Raw materials and purchased parts $ 4,176 $ 4,092 Work in progress 1,870 3,166 Finished goods 26,584 21,529 Total inventories $ 32,630 $ 28,787

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Property and Equipment, Net	4. Property and equipment, net, consists of the following (in thousands): December 31, 2019 2018 Land $ 1,117 $ 1,132 Equipment 6,724 6,236 Furniture and fixtures 578 640 Computer hardware 3,142 2,118 Leasehold improvements 2,792 1,380 Construction in process 14,758 3,826 Property and equipment, gross 29,111 15,332 Less: accumulated depreciation (5,958 ) (3,885 ) Property and equipment, net $ 23,153 $ 11,447 Depreciation expense amounted to $2.0 million, $1.7 million, and $2.1 million for the years ended December 31, 2019, 2018, and 2017, respectively.

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	12 Months Ended
	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	5. Goodwill The changes in the carrying amount of goodwill for each reporting unit to which goodwill is assigned for the periods indicated are as follows (in thousands): Global Supply Chain Oncology Innovation Platform Total Balance as of January 1, 2018 $ 26,510 $ 11,285 $ 37,795 Effect of currency translation adjustment (277 ) (23 ) (300 ) Balance as of December 31, 2018 26,233 11,262 37,495 Goodwill acquired — 1,018 1,018 Effect of currency translation adjustment (64 ) 64 — Balance as of December 31, 2019 $ 26,169 $ 12,344 $ 38,513 Intangible Assets, Net The Company’s identifiable intangible assets, net, consist of the following (in thousands): December 31, 2019 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 8,935 $ 3,561 $ — $ 5,374 Polymed customer list 1,593 1,164 — 429 Polymed technology 3,712 1,297 — 2,415 Product rights 530 360 170 — Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 728 — — 728 Effect of currency translation adjustment (424 ) — — (424 ) Total intangibles, net $ 15,074 $ 6,382 $ 170 $ 8,522 December 31, 2018 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 8,935 $ 2,060 $ — $ 6,875 Polymed customer list 1,593 938 — 655 Polymed technology 3,712 999 — 2,713 Product rights 530 263 — 267 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,026 — 298 728 Effect of currency translation adjustment (390 ) — — (390 ) Total intangibles, net $ 15,406 $ 4,260 $ 298 $ 10,848 As of December 31, 2019, licenses at cost include an Orascovery license of $0.4 million and licenses purchased from Gland Pharma Ltd (“Gland”) of $4.5 million, and a license purchased from MAIA Pharmaceuticals, Inc. (“MAIA”) for $4.0 million. The Orascovery license with Hanmi Pharmaceuticals Co. Ltd. (“Hanmi”) was purchased directly from Hanmi and is being amortized on a straight-line basis over a period of 12.75 years, the remaining life of the license agreement at the time of purchase. The licenses purchased from Gland are being amortized on a straight-line basis over a period of 5 years, the remaining life of the license agreement at the time of purchase. The license purchased from MAIA is being amortized over a period of 7 years, the remaining life of the license agreement at the time of purchase. The remaining intangible assets were acquired in connection with the acquisitions of Athenex Pharma Solutions (“APS” or “Athenex Pharma Solutions”) (formerly known as QuaDPharma), Polymed Therapeutics, Inc. (“Polymed”), Comprehensive Drug Enterprises (“CDE”). Intangible assets are amortized using the straight-line method over their useful lives. The APS customer list is amortized on a straight-line basis over 7 years. The Polymed customer list and technology are amortized on a straight-line basis over 6 and 12 years, respectively. The CDE in-process research and development (“IPR&D”), will not be amortized until the related projects are completed. IPR&D is tested annually for impairment, unless conditions exist causing an earlier impairment test (e.g., abandonment of project). During the year ended December 31, 2019, the Company determined that its product rights, initially acquired as IPR&D in connection with the acquisition of CDE, was impaired due to a lack of forecasted sales and therefore, the related balance of $0.2 million was written-off as impaired and is included within research and development expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2019. During each of the years ended December 31, 2018 and 2017, the Company abandoned projects within IPR&D and therefore, the related balances of $0.3 million and $0.1 million, respectively, were written-off as impaired and were included within research and development expenses in the consolidated statement of operations and comprehensive loss. The weighted-average useful life for all intangible assets was 7.7 years as of December 31, 2019. The Company recorded $1.9 million, $1.6 million, and $1.6 million of amortization expense for the years ended December 31, 2019, 2018, and 2017, respectively. The Company expects amortization expense related to its finite-lived intangible assets for the next 5 years and thereafter to be as follows as of December 31, 2019 (in thousands): Year ending December 31: Estimated Amortization Expense 2020 $ 2,138 2021 1,782 2022 1,011 2023 982 2024 941 Thereafter 1,364 $ 8,218

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	6. Financial instruments consist of cash and cash equivalents, short-term investments, an equity investment, accounts receivable, accounts payable, accrued liabilities, and debt. Short-term investments and the equity investment are stated at fair value. Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts. ASC 820, Fair Value Measurements Level 1 —Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the plan has the ability to access. Level 2 —Inputs to the valuation methodology include: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets or liabilities in inactive markets; • Inputs other than quoted prices that are observable for the asset or liability; • Inputs that are derived principally from or corroborated by observable market data by correlation or other means; and • If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3 —Inputs to the valuation methodology are unobservable, supported by little or no market activity, and that are significant to the fair value measurement. Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs; there were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during the years ended December 31, 2019, 2018, or 2017. The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at December 31, 2019 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 5,460 $ 5,460 $ — $ — Short-term investments - certificates of deposit 15,110 — 15,110 — Short-term investments - commercial paper 51,017 — 51,017 — Financial assets included within short-term investments Short-term investments - certificates of deposit 10,054 — 10,054 — Short-term investments - commercial paper 22,835 — 22,835 — Available-for-sale investment 250 250 — — Total assets $ 104,726 $ 5,710 $ 99,016 $ — Fair Value Measurements at December 31, 2018 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 25 $ 25 $ — $ — Short-term investments - commercial paper 5,396 — 5,396 — Financial assets included within short-term investments Short-term investments - commercial paper 36,544 — 36,544 — Short-term investments - corporate notes 16,699 — 16,699 — Short-term investments - U.S. government bonds 3,998 — 3,998 — Available-for-sale investment 388 388 — — Total assets $ 63,050 $ 413 $ 62,637 $ — The Company classifies its certificates of deposit and money market funds within Level 1 because it uses quoted market prices to determine their fair value. The Company classifies its commercial paper, corporate notes, certificates of deposit, and U.S. government bonds within Level 2 because it uses quoted prices for similar assets or liabilities in active markets and each has a specified term and all level 2 inputs are observable for substantially the full term of each instrument. The Company owns 68,000 shares of PharmaEssentia, a company publicly traded on the Taiwan OTC Exchange. As of December 31, 2019 and 2018, the Company’s investment in PharmaEssentia is valued at the reported closing price. This investment is classified as a level 1 investment and is recorded as an available-for-sale investment within short-term investments on the Company’s consolidated balance sheet.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
ACQUISITIONS	7. CIDAL On June 27, 2019, the Company entered into a definitive asset purchase agreement (“the APA”) with CIDAL Limited, a British Virgin Islands company limited by shares, and several of its affiliates (“CIDAL”). CIDAL operates as a contract research organization with headquarters in Guatemala and operations in various countries in Latin America. Pursuant to the terms of the APA, the Company acquired certain assets of CIDAL in exchange issuing milestone payments of an aggregate of 67,796 shares of the Company’s common stock upon the achievement of certain developmental and regulatory events through the third quarter of 2021. The transactions contemplated by the asset purchase agreement closed on October 31, 2019. The Company believes the acquisition strategically strengthens the Company’s clinical research and operations capabilities and further supports its clinical development worldwide. The Company accounted for the asset purchase using the acquisition method of accounting and accordingly, the identifiable assets acquired and liabilities assumed were recorded based upon management’s estimates of current fair values as of the acquisition date. The purchase price reflected contingent equity consideration associated with this transaction. The Company received net cash of $0.9 million, acquired property and equipment of less than $0.1 million, assumed liabilities of $1.1 million, and recorded goodwill of approximately $1.0 million in the Oncology Innovation Platform, as well as contingent equity consideration associated with the transaction of $0.8 million. AXIS On June 29, 2018, the Company entered into a Share Subscription Agreement (“SSA”) for Axis Therapeutics Limited (“Axis”), a subsidiary of the Company jointly owned by Athenex and Xiangxue Life Sciences Limited (“XLifeSc”). Under the SSA, Athenex contributed $30.0 million cash for a 55% ownership interest in Axis and XLifeSc contributed a license for IPR&D of certain immunotherapy technology for a 45% ownership interest in Axis. Also, on June 29, 2018, through a license agreement entered into between XLifeSc and Axis, XLifeSc granted Axis an exclusive, sublicensable worldwide (excluding mainland China) right and license to use its proprietary TCR-engineered T Cell therapy to develop and commercialize products for oncology indications (“TCR-T License”). Upon effectiveness of the TCR-T License and satisfaction of certain conditions of the license agreement, the Company issued 267,952 shares of its common stock equal to $5.0 million to XLifeSc. On September 14, 2018, Athenex completed the $30.0 million cash injection to Axis and all the closing conditions under the SSA were fulfilled. The Company has consolidated the financial statements of Axis into its consolidated financial statements as of and for the years ended December 31, 2019 and 2018 using the voting interest model. The nonmonetary exchange of 45% of the shares of Axis for the IPR&D from XLifeSc has been accounted for as an asset acquisition that does not constitute a business under ASC 805. Therefore, the acquisition of IPR&D was expensed as research and development expense at its fair value. The Company determined that the fair value of the equity issued to XLifeSc was $24.5 million for the IPR&D, considering the $30.0 million contribution made by the Company for its 55% ownership interest and the arms-length nature of the transaction. Accordingly, the Company recorded an expense of $24.5 million within research and development expenses on its consolidated statements of operations and comprehensive loss for the year ended December 31, 2018. On September 27, 2019, the Company executed a sponsorship agreement whereby Athenex will sponsor and conduct all Investigation New Drug applications with the U.S. FDA arising from the TCR-T platform. Axis will pay a fee to the Company for these services and will reimburse Athenex for all costs incurred in connection with the work performed. For the year ended December 31, 2019, the Company charged Axis $1.2 million for these expenses. This amount is included within research and development expenses. The minority interests’ portion of these expenses is recorded within net loss attributable to non-controlling interests on the Company’s consolidated statements of operations and comprehensive loss.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Accrued Expenses	8 . Accrued expenses consist of the following (in thousands): December 31, 2019 2018 Accrued wages and benefits $ 7,541 $ 5,061 Accrued clinical expenses 2,510 2,653 Accrued operating expenses 1,885 8,128 Deferred revenue 218 190 Accrued R&D licensing fees 384 4,827 Accrued inventory purchases 7,194 — Accrued tax withholdings 187 — Accrued selling fees and rebates 1,577 423 Accrued construction costs 22,811 16,436 Total accrued expenses $ 44,307 $ 37,718 The accrued construction costs relate to the building of the manufacturing facility in Dunkirk, NY (Note 12 – Business and Economic Collaborative Agreements December 31, 2019

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9 . On December 22, 2017, the Tax Cuts and Jobs Act (Tax Reform Act) was signed into law. This legislation significantly changes U.S. tax law by, among other things, lowering corporate income tax rates, implementing a territorial tax system and imposing a repatriation tax on deemed repatriated earnings of foreign subsidiaries. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. As a result of the reduction in the U.S. corporate income tax rate from 35% to 21% under the Tax Reform Act, the Company revalued its net U.S. deferred income tax liabilities at December 31, 2017. The Company has reduced its income tax expense from continuing operations by approximately $34.1 million due to the revaluation of U.S. deferred tax liabilities, offset by an increase in the valuation allowance. The valuation allowance for deferred tax assets increased by $32.3 million for the year ended December 31, 2019 and increased by $28.1 million for the year ended December 31, 2018. The change in the valuation allowance was due to an increase of deferred tax assets mainly for additional net operating losses and tax credit carryforwards. The Company has provided a full valuation allowance against its deferred tax assets as it has determined that it is not more likely than not that recognition of such deferred tax assets will be utilized in the foreseeable future. The Tax Reform Act provided for a one-time deemed mandatory repatriation of post-1986 undistributed foreign subsidiary earnings and profits (“E&P”) through the year ended December 31, 2017. The one-time transition tax is based on the Company’s total post-1986 earnings and profits for which it has previously deferred from U.S. income taxes. The Company did not record amounts in income tax expense for the transition tax as it has accumulated losses in its foreign subsidiaries, and thus was not subject to the transition tax. While the Tax Reform Act provides for a territorial tax system, beginning in 2018, it also includes two new U.S. tax base erosion provisions - the global intangible low-taxed income (“GILTI”) provisions and the base-erosion and anti-abuse tax (“BEAT”) provisions. The GILTI provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company does not expect that it will be subject to incremental U.S. tax on GILTI income beginning in 2018. In the event that the Company is subject to this tax, it has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred. The BEAT provisions in the Tax Reform Act eliminates the deduction of certain base-erosion payments made to related foreign corporations and impose a minimum tax if greater than regular tax. The Company does not expect to be impacted by this tax based on annual gross receipts threshold for 2018. On December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin (“SAB”) No. 118 to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Reform Act. The Company has recognized the tax impacts related to the revaluation of deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December 31, 2018. The Company recorded an income tax expense of $0.9 million during the year ended December 31, 2019 and an income tax expense of $0.1 million during each of the years ended December 31, 2018 and 2017. The current and prior year income tax expense is attributable to foreign withholding taxes. The Company and its other subsidiaries were in a cumulative loss position as of December 31, 2019. The components of loss before income tax expense consist of the following (in thousands): Year Ended December 31, 2019 2018 2017 Domestic $ (109,769 ) $ (95,479 ) $ (125,770 ) Foreign (14,836 ) (33,132 ) (5,541 ) $ (124,605 ) $ (128,611 ) $ (131,311 ) The components of the income tax expense consist of the following (in thousands): Year Ended December 31, 2019 2018 2017 Current: Federal $ — $ — $ 64 State 23 27 (92 ) Foreign 419 455 440 442 482 412 Deferred: Federal (26,878 ) (26,260 ) (3,222 ) State (2,567 ) (293 ) 5,799 Foreign (2,411 ) (1,863 ) (874 ) (31,856 ) (28,416 ) 1,703 Change in valuation allowance 32,342 28,034 (2,030 ) $ 928 $ 100 $ 85 The income tax expense differs from the federal statutory rate due to the following: Year Ended December 31, 2019 2018 2017 Statutory rate 21.0 % 21.0 % 34.0 % State taxes, net of federal benefit 2.0 0.2 (4.3 ) Foreign rate differential 0.1 (0.3 ) (0.6 ) Federal income tax rate change — — (25.9 ) Valuation allowance (25.9 ) (21.6 ) 1.5 Other 2.1 0.6 (4.8 ) (0.7 )% (0.1 )% (0.1 )% Net deferred income tax assets consist of the following (in thousands): December 31, 2019 2018 Intangible assets $ 11,348 $ 10,273 Property and equipment 77 238 Stock-based compensation 9,551 7,508 Net operating loss carryforwards 81,630 60,362 Tax credit carryforwards 9,191 5,341 Research and development deduction 1,493 - Reserves and accruals 8,377 6,141 Gross deferred income tax assets 121,667 89,863 Less: valuation allowance (120,805 ) (88,455 ) Net deferred income tax assets 862 1,408 Intangible assets (862 ) (922 ) Gross deferred income tax liabilities (862 ) (922 ) Net deferred income tax assets $ — $ 486 As of December 31, 2019, there exists $340.7 million federal net operating losses and $74.2 million of state net operating losses, respectively. Of the federal net operating losses, $184.8 million expire beginning in 2027 and $155.9 million have an indefinite life. In addition, there exists $28.5 million of foreign net operating losses as of December 31, 2019 which may be carried forward indefinitely. The Company considers whether any positions taken on the Company’s income tax returns would be considered uncertain tax positions that may require the recognition of a liability. The Company has concluded that there are no material uncertain tax positions as of December 31, 2019, 2018, and 2017. The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income benefit in the consolidated statement of operations and comprehensive loss. There were no amounts recognized for interest and penalties related to unrecognized tax benefits during the years ended December 31, 2019, 2018, and 2017. The income tax returns for the taxable years 2013 to 2018 in the U.S., China, and Hong Kong remain open and subject to income tax audits. Provision has not been made for U.S. taxes on undistributed earnings of foreign subsidiaries. Those earnings, if any, have been and will continue to be indefinitely reinvested. Under the provisions of Section 382 of the Internal Revenue Code (“IRC”), net operating loss and credit carryforwards and other tax attributes may be subject to limitation if there has been a significant change in ownership of the Company, as defined by the IRC. Changes in ownership of our common stock could result in limitations on net operating loss carryforwards.

Debt and Lease Obligations

Debt and Lease Obligations	12 Months Ended
	Dec. 31, 2019
Debt And Lease Obligations [Abstract]
Debt and Lease Obligations	1 0 . Debt The Company’s debt as of December 31, 2019 and 2018, consists of the following (in thousands): December 31, 2019 2018 Current portion of mortgage $ 686 $ 779 Current portion of finance and capital lease obligations 194 182 Current portion of operating lease obligations 3,010 — Long-term portion of finance and capital lease obligations 227 422 Long-term portion of operating lease obligations 7,620 — Chongqing Maliu credit agreement 5,731 — Senior secured loan, net of debt discount and financing fees of $3,592 and $4,619, respectively 46,408 45,381 Total $ 63,876 $ 46,764 The mortgage payments, assumed in connection with the acquisition of CDE, extend through December 31, 2020. During 2018, Perceptive issued a senior secured loan to the Company with a principal value of $50.0 million and a maturity date of June 30, 2023. The loan bears interest at a floating per annum rate equal to LIBOR (with a floor of 2.0%) plus 9.0%. The Company is required to make monthly interest-only payments with a bullet payment of the principal at maturity. Provided that, in the event LIBOR can no longer be determined, the parties shall mutually establish an alternative rate of interest and until such time that rate is agreed, the reference rate for purposes of the loan shall be the Wall Street Journal Prime Rate. During the first quarter of 2019, the Company was issued an unsecured, subordinated bank loan from China Merchants Bank to fund operations in China. This loan had a principal value of $0.7 million, a maturity date of December 11, 2019, and bore interest at a fixed rate of 5.7% annually. The loan was paid in full as of December 31, 2019. During the second quarter of 2019, the Company entered into a credit agreement which amended the existing partnership agreement with Chongqing Maliu Riverside Development and Investment Co., LTD (“CQ”), for a Renminbi ¥50.0 million (USD $7.2 million at December 31, 2019) line of credit to be used for the construction of the new active pharmaceutical ingredient (“API”) plant in China. The Company is required to repay the principal amount with accrued interest within three years after the plant receives the U.S. Current Good Manufacturing Practices (“cGMP”) certification, with 20% of the total loan with accrued interest is due within the first twelve months following receiving the certification, 30% of the total loan with accrued interest due within twenty-four months, and the remaining balance with accrued interest due within thirty-six months. Interest accrues at the three-year loan interest rate by the People’s Bank of China for the same period on the date of the deposit of the full loan amount, which is expected to approximate 4.75% annually. If the Company fails to obtain the cGMP certification within three years upon the acceptance of the plant, it shall return all renovation costs with the accrued interest to CQ in a single transaction within the first ten business days. As of December 31, 2019, the balance due to CQ was $5.7 million. Lease Obligations As described in Note 2- Summary of Significant Accounting Policies Leases (Topic 842) The Company has operating leases for office and manufacturing facilities in several locations in the U.S., Asia, and Latin America, and has three finance leases for manufacturing equipment used in its facilities near Buffalo, NY (See Note 19 – Commitments and Contingencies) Year Ended December 31, 2019 Operating lease cost $ 3,162 Finance lease cost: Amortization of assets 81 Interest on lease liabilities 31 Total net lease cost $ 3,274 The Company has elected to exclude short-term leases from its operating lease ROU assets and lease liabilities. Lease costs for short-term leases were not material to the financial statements for the year ended December 31, 2019. Variable lease costs for the year ended December 31, 2019 were not material to the financial statements. Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): December 31, 2019 Finance leases: Property and equipment, at cost $ 688 Accumulated amortization, net (109 ) Property and equipment, net $ 579 Current obligations of finance leases $ 194 Long-term portion of finance leases 227 Total finance lease obligations $ 421 Weighted average remaining lease term (in years): Operating leases 5.21 Finance leases 2.11 Weighted average discount rate: Operating leases 12.9 % Finance leases 5.9 % Supplemental cash flow information related to leases is as follows (in thousands): Year Ended December 31, 2019 Cash paid for amount included in the measurements of lease liabilities: Operating cash flows from operating leases $ 3,374 Operating cash flows from finance leases 31 Financing cash flows from finance leases 183 ROU assets recognized in exchange for new operating lease obligations $ 1,305 Future minimum payments and maturities of leases is as follows (in thousands): Year ending December 31: Operating Leases Finance Leases 2020 $ 3,229 $ 214 2021 2,843 214 2022 2,623 21 2023 2,096 — 2024 2,002 — Thereafter 1,950 — Total lease payments 14,743 449 Less: Imputed interest (4,113 ) (28 ) Total lease obligations 10,630 421 Less: Current obligations (3,010 ) (194 ) Long-term lease obligations $ 7,620 $ 227 Pursuant to the public-private partnership agreements with the State of New York and CQ, the Company will rent the manufacturing facilities from the government with favorable terms. As of December 31, 2019, construction of API plant was complete. However, the lease terms had not started, both facilities were not yet operational, and no lease costs occurred in 2019. (See Note 12 – Business and Economic Collaborative Agreements – Commitments and Contingencies) The Company exercises judgment in determining the discount rate used to measure the lease liabilities. When rates are not implicit within an operating lease, the Company uses its incremental borrowing rate as its discount rate, which is based on yield trends in the biotechnology and healthcare industry and debt instruments held by the Company with stated interest rates. The Company re-assesses its incremental borrowing rate when new leases arise, or existing leases are modified.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	1 1 . During the years ended December 31, 2019, 2018, and 2017, the Company entered into transactions with individuals and other companies that have financial interests in the Company. Related party transactions included the following: a. In 2015, CDE signed an agreement with Avalon BioMedical (Management) Limited and its subsidiaries (“Avalon”) under which Avalon would receive certain administrative services and would occupy space at CDE’s research location. Avalon would reimburse CDE for these administrative services as incurred and pay CDE a percentage of the total rent payment based on its staff headcount occupying the Hong Kong research and development facility (See Note 19— Commitments and Contingencies In June 2018, the Company entered into two in-licensing agreements with Avalon wherein the Company obtained certain intellectual property (“IP”) from Avalon to develop and commercialize the underlying products. Under these agreements the Company is required to pay upfront fees, future milestone payments, and sales-based royalties. During the year ended December 31, 2018, the Company recorded $5.5 million of upfront fees, consisting of $3.5 million in cash and $2.0 million in equity, as research and development expense on its 2018 consolidated statement of operations and comprehensive loss. During the year ended December 31, 2018, 107,181 shares of common stock were issued to Avalon at a price of $18.66 per share, the closing price of the stock on the date the agreement was executed, in connection with the license agreements. During the year ended December 31, 2019, the Company recorded a $1.0 million milestone fee paid to Avalon, as research and development expenses on its consolidated statement of operations and comprehensive loss. In June 2019, the Company entered into an agreement whereby Avalon will hold a 90% ownership interest and the Company will hold a 10% ownership interest of the newly formed entity under the name Nuwagen Limited (“Nuwagen”), incorporated under the laws of Hong Kong. Nuwagen is principally engaged in the development and commercialization of herbal medicine products for metabolic, endocrine, and other related indications. The Company will contribute nonmonetary assets in exchange for the 10% ownership interest. As of December 31, 2019, the transaction has not closed. b. The Company earns licensing revenue from PharmaEssentia, an entity in which the Company has an investment classified as available-for-sale (see Note 6 — Fair Value Measurements c. The Company receives certain clinical development services from ZenRx Limited and its subsidiaries (“ZenRx”), a company for which one of our executive officers serves on the board of directors. In connection with such services, the Company made payments to ZenRx of $2.7 million, $0.3 million, and $0.6 million for the years ended December 31, 2019, 2018, and 2017, respectively. In April 2013, the Company entered into a license agreement with ZenRx pursuant to which the Company granted an exclusive, sublicensable license to use certain of the Company’s IP to develop and commercialize oral irinotecan and encequidar, and oral paclitaxel and encequidar in Australia and New Zealand, and a non-exclusive license to manufacture a certain compound, but only for use in oral irinotecan and encequidar and oral paclitaxel and encequidar. ZenRx is responsible for all development, manufacturing and commercialization, and the related costs and expenses, of any product candidates resulting from the agreement. No revenue was earned from this license agreement in the periods presented in these consolidated financial statements. d. The Company received consulting services from RSJ Consulting LLC (“RSJ”), a limited liability company for which one of our executive officers serves as the principal. Services incurred from RSJ amounted to $0 for the years ended December 31, 2019 and 2018, and $0.1 million for the year ended December 31, 2017, respectively. e . During the first quarter of 2017, the Company issued and sold $4.0 million in convertible bonds to two related parties. One of the holders of more than 5% of our outstanding common stock as of the IPO date and a director of the Company each purchased $2.0 million in convertible bonds. In June 2017, these bonds were converted into 2,727,273 shares of common stock. f . Certain family members of our executive officers perform consulting services to the Company. Such services were not significant to the consolidated financial statements.

Business and Economic Collabora

Business and Economic Collaborative Agreements	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Business and Economic Collaborative Agreements	1 2 . New York State On May 1, 2015, the Company executed an agreement for a medical technology research, development, innovation, and commercialization alliance with Fort Schuyler Management Corporation (“FSMC”), a not-for-profit corporation existing under the laws of the State of New York (the “State”). Under the agreement, FSMC agreed to pay up to $25.0 million for the construction of our North American headquarters and formulation lab and equipment in Buffalo, New York. The Company moved into the North American Headquarters in October 2015 and is sub-leasing the space from FSMC for a 10-year term, with an option to extend the term for an additional 10 years. The Company, through its partnership with FSMC, Empire State Development (“ESD”), and The State University of New York (“SUNY”) Polytechnic, was to complete the construction of an ISO Class 5 high potency oral and sterile injectable pharmaceutical manufacturing facility in Dunkirk, New York. This manufacturing facility, which was originally planned to be 320,000 square feet, has been expanded to approximately 409,000 square feet to meet the required needs of the Company and within the terms of the September 2017 agreement. On September 4, 2017, the Company entered into a Grant Disbursement Agreement whereby the State agreed to grant up to approximately $208.0 million, which includes approximately $8.0 million in additional funds available from the previous $25.0 million ESD Grant for the Company’s corporate offices, to fund the construction of the new pharmaceutical manufacturing facility. If construction costs exceed $208.0 million, the Company is responsible for funding those construction costs. The Company is also responsible for the costs of furnishing the facility. The Company is entitled to lease the facility and all equipment purchased with grant funds at a rate of $1.00 per year for an initial 10-year term, and for the same rate if the Company elects to extend the lease for an additional 10-year term. In exchange, the Company committed to spending $1.52 billion on operational expenses in the facility in its first 10-year term, and an additional $1.50 billion on operational expenses if the Company elects to extend the lease for a second 10-year term. The State will hold ownership of the manufacturing and office facilities. Construction of these facilities has begun and is expected to be completed in 2021. Chongqing Government Department of Economic Development In October 2015, the Company completed and executed an agreement with the Banan District in Chongqing, China (“CQ”) to construct a cGMP API manufacturing plant of approximately 440,000 square feet and a GMP pharmaceutical manufacturing plant of approximately 510,000 square feet on Banan sites identified and selected by the Company’s management. Under the terms of the agreement, Banan will provide the funding for the land and construction of the manufacturing plants according to Athenex specifications and the Company will equip the plant. This agreement allows the Company to expand its existing high potency oncology active pharmaceutical ingredient manufacturing capacity as well as its drug manufacturing capacity in China. The Company does not have significant construction period risks and the Banan District will fund the construction costs and hold ownership of the facilities. Pursuant to the agreement, the Company is committed to a registration capital requirement of no less than $30.0 million, which can be used as working capital in the course of the business. As of December 31, 2019, the Company had contributed a total of $9.5 million registration capital to its subsidiary set up under the agreement. The land and buildings will be owned by CQ, and we will lease the facilities, rent-free, for the first 10-year term, with an option to extend the lease for an additional 10-year term, during which, if we are profitable, we will pay a monthly rent of 5 RMB per square meter of space occupied. In addition, the Company is responsible for the costs of all equipment and technology for the facilities. Construction on the new API plant has been completed. However, as a result of delays attributable to the outbreak of Coronavirus, we expect to commence operations at our new API facility in Chongqing in the second half of 2020. In connection with these arrangements with FSMC and the Banan District we have committed to certain operational milestones. If we are unable to comply with such, we may lose access to these properties.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	1 3 . Common Stock Option Plans The Company has four equity compensation plans, adopted in 2017, 2013, 2007 and 2004 (the “Plans”) which, taken together, authorize the grant of up to 16,000,000 shares of common stock to employees, directors, and consultants. On May 23, 2019, the board of directors approved the amendment and restatement of the 2017 Omnibus Incentive Plan, which increases the number of shares available for issuance under the 2017 plan by up to 500,000 shares, subject to the approval of the Company’s stockholders at the Company’s 2020 annual meeting of stockholders. Additionally, on June 14, 2017, the Company adopted its 2017 Employee Stock Purchase Plan (the “ESPP”), which authorizes the issuance of up to 1,000,000 shares of common stock for future issuances to eligible employees. Stock Options The total fair value of stock options vested and recorded as compensation expense during the year ended December 31, 2019 , 2018 , and 2017 was $7.9 million, $9.8 million, and $8.0 million, respectively. As of December 31, 2019 , $14.9 million of unrecognized cost related to non-vested stock options was expected to be recognized over a weighted-average period of approximately 1.7 Years. T he total intrinsic value of options exercised was approximately $2.7 million and $6.7 million for the years ended December 31, 2019 and 2018 , respectively. The following table summarizes the status of the Company’s stock option activity granted under the Plans and 2017 Plans to employees, directors, and consultants (in thousands, except stock option amounts and exercise price): Stock options granted have a contractual term of 10 years and generally vest over a 2-4 year period. A limited number of stock options vest immediately in certain circumstances. Stock Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2018 10,687,650 $ 8.51 6.87 $ 44,688 Granted 875,000 13.14 — Exercised (331,779 ) 5.86 — Forfeited (165,488 ) 13.95 — Expired (148,447 ) 8.51 — Outstanding at December 31, 2019 10,916,936 $ 8.88 5.68 $ 69,785 Vested and exercisable at December 31, 2019 8,292,953 $ 7.19 4.90 $ 67,012 The Company determines the fair value of stock option awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding a number of highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes option pricing model during the periods indicated: Year Ended December 31, 2019 2018 2017 Weighted average grant date fair value $ 8.06 $ 9.80 $ 7.01 Expected dividend yield — % — % — % Expected stock price volatility 64 % 59 % 66 % Risk-free interest rate 2.60 % 2.61 % 1.74 % Expected life of options (in years) 6.3 6.1 6.2 Restricted Stock Awards During the year ended December 31, 2019, the Company granted 92,723 restricted stock awards to employees in lieu of a cash bonus. Stock-based compensation related to this stock award amounted to $1.1 million for the year ended December 31, 2019. The Company granted 131,000 restricted stock awards to employees during the year ended December 31, 2019. Stock-based compensation related to the restricted stock awards amounted to $0.6 million for the year ended December 31, 2019. As of December 31, 2019, $1.5 million of unrecognized cost related to non-vested restricted stock awards were expected to be recognized over a weighted-average period of approximately 0.5 years. Employee Stock Purchase Plan The ESPP is available to eligible employees (as defined in the plan document). Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from December 1, 2019 to May 31, 2020. The Company expects to offer six-month offering periods after the current period. The 2017 Plans reserved 1,000,000 shares of common stock for issuance under the ESPP. Stock-based compensation related to the ESPP amounted to $0.3 million for the year ended December 31, 2019 , $0.2 million for the year ended December 31, 2018, and $0 for all preceding periods. The Company issued 60,825 and 41,733 shares of common stock to participants during the years ended December 31, 2019 and 2018, respectively. Stock-Based Compensation Cost The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the years ended December 31, 2019, 2018, and 2017 (in thousands): Year Ended December 31, 2019 2018 2017 Stock options $ 7,887 $ 9,786 $ 8,031 Restricted stock expense 566 1,008 2,160 Stock awarded to directors and officers 1,105 — 4,400 Employee stock purchase plan 327 217 — Total stock-based compensation expense $ 9,885 $ 11,011 $ 14,591 Cost of sales $ 248 $ 228 $ 137 Research and development expenses 3,251 2,621 2,030 Selling, general, and administrative expenses 6,386 8,162 12,424 Total stock-based compensation expense $ 9,885 $ 11,011 $ 14,591

Net Loss per Share Attributable

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Athenex, Inc. Common Stockholders	1 4 . Basic net loss per share is calculated by dividing net loss attributable to Athenex, Inc. common stockholders by the weighted-average number of common shares issued, outstanding, and vested during the period. Diluted net loss per share is computed by dividing net loss attributable to Athenex, Inc. common stockholders by the weighted-average number of common share and common shares equivalents for the period using the treasury-stock method. For the purposes of this calculation, warrants for common stock and stock options are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following weighted average outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable Athenex, Inc. to common stockholders for the periods presented because including them would have been antidilutive: Year Ended December 31, 2019 2018 2017 Stock options and other common stock equivalents 10,814,635 10,480,084 9,534,658 Unvested restricted common shares 45,581 113,260 393,408 Total potential dilutive common shares 10,860,216 10,593,344 9,928,066

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Accumulated Other Comprehensive Loss	1 5 . The components and changes of accumulated other comprehensive loss, net of related income tax effects, are as follows (in thousands): Balance as of January 1, 2017 $ (1,304 ) Foreign currency translation adjustment 1,184 Unrealized loss on investment (26 ) Balance as of December 31, 2017 (146 ) Foreign currency translation adjustment (525 ) Unrealized loss on investment 15 Balance as of December 31, 2018 (656 ) Foreign currency translation adjustment 118 Unrealized gain on investment (97 ) Balance as of December 31, 2019 $ (635 )

Business Segment, Geographic, a

Business Segment, Geographic, and Concentration Risk Information	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Business Segment, Geographic, and Concentration Risk Information	1 6 . The Company has three operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue (only applicable to two reportable segments). Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. Consequently, the Company has concluded each operating segment to be a reportable segment. The Company’s operating segments are as follows: Oncology Innovation Platform — This operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. It focuses specifically on Orascovery and Src Kinase Inhibition research platforms, and TCR-T Immunotherapy and Arginine Deprivation Therapy. This segment operates in the United States, Taiwan, Hong Kong, mainland China, the United Kingdom, and Latin America. Global Supply Chain Platform — This operating segment includes APS and Polymed. APS is a contract manufacturing company that provides small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies and for use as internal supplies to the clinical studies and commercial development of the Company’s proprietary drugs. APS also performs microbiological and analytical testing for raw material and formulated products and has expanded to manufacture and sell pharmaceutical products under Section 503B of the Compounding Quality Act within the Federal Food, Drug & Cosmetic Act (“FDCA”). Polymed markets and sells API in North America, Europe, and Asia from its locations in Texas and China. Polymed also develops new compounds and processing techniques, and recently completed construction of a new API manufacturing facility in Chongqing, China (see Note 12— ). However, as a result of the Coronavirus outbreak, the 440,000-square-foot facility is expected to commence operations in the second half of 2020. The Company has an existing API manufacturing facility in Chongqing, China, where operations are currently suspended. Commercial Platform — This operating segment includes APD, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. This segment provides services and products to external customers based mainly in the United States. The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the United States, Taiwan, Hong Kong, mainland China, and the United Kingdom. The Global Supply Chain Platform segment operates and holds long-lived assets located in the United States and China. The Commercial Platform segment operates and holds long-lived assets located in the United States. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer. Segment information is as follows (in thousands): Year Ended December 31, 2019 2018 2017 Total revenue: Oncology Innovation Platform $ 20,562 $ 32,776 $ 1,411 Global Supply Chain Platform 33,970 31,274 28,427 Commercial Platform 50,427 30,426 17,218 Total revenue for reportable segments 104,959 94,476 47,056 Intersegment revenue (3,730 ) (5,376 ) (9,013 ) Total consolidated revenue $ 101,229 $ 89,100 $ 38,043 Intersegment revenue eliminated in the above table reflects sales from the Global Supply Chain Platform to the Oncology Innovation Platform. Year Ended December 31, 2019 2018 2017 Total revenue by product group: API sales $ 12,733 $ 17,952 $ 15,351 Medical device sales — 2,344 1,747 Contract manufacturing revenue 391 458 1,360 Commercial product sales 67,411 35,640 17,648 License fees 20,100 32,000 750 Consulting 396 387 355 Grant revenue 198 319 832 Total consolidated revenue $ 101,229 $ 89,100 $ 38,043 Intersegment revenue is recorded by the selling segment when it is realized or realizable and all revenue recognition criteria are met. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger. Year Ended December 31, 2019 2018 2017 Net loss attributable to Athenex, Inc.: Oncology Innovation Platform $ (100,919 ) $ (89,912 ) $ (108,563 ) Global Supply Chain Platform (8,575 ) (16,858 ) (7,179 ) Commercial Platform (14,255 ) (10,670 ) (15,428 ) Total consolidated net loss attributable to Athenex, Inc. $ (123,749 ) $ (117,440 ) $ (131,170 ) Year Ended December 31, 2019 2018 2017 Total depreciation and amortization Oncology Innovation Platform $ 762 $ 690 $ 482 Global Supply Chain Platform 1,489 1,603 2,272 Commercial Platform 1,566 976 919 Total consolidated depreciation and amortization $ 3,817 $ 3,269 $ 3,673 December 31, 2019 2018 Total assets: Oncology Innovation Platform $ 194,183 $ 135,878 Global Supply Chain Platform 63,598 58,816 Commercial Platform 52,151 36,401 Total assets $ 309,932 $ 231,095 Year Ended December 31, 2019 2018 2017 Total revenue United States $ 67,794 $ 37,904 $ 19,933 Spain 20,000 30,000 — Austria 4,422 9,569 3,962 India 3,066 3,457 8,479 China 2,105 4,416 2,803 United Kingdom 1,023 — — Taiwan — — 500 Other foreign countries 2,819 3,754 2,366 Total consolidated revenue $ 101,229 $ 89,100 $ 38,043 December 31, 2019 2018 Total property and equipment, net: United States $ 11,486 $ 6,549 China 11,667 4,898 Total property and equipment, net $ 23,153 $ 11,447 Customer revenue and accounts receivable concentration amounted to the following for the identified periods: Year Ended December 31, 2019 2018 2017 Percentage of total revenue by customer: Customer A 20 % 34 % — Customer B 16 % 12 % 15 % Customer C 15 % 9 % 6 % Customer D 14 % 9 % 7 % Customer E 4 % 4 % 19 % December 31, 2019 2018 Percentage of total accounts receivable by customer: Customer A 45 % 18 % Customer B 31 % 16 % Customer C 10 % — Customer D — 12 %

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Revenue Recognition	17. The Company records revenue in accordance with ASC, Topic 606 “ Revenue from Contracts with Customers .” Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the entity performs the following five steps: (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Below is a description of principal activities – separated by reportable segments – from which the Company generates its revenue (See Note 16 – Business Segment, Geographic, and Concentration Risk Information ). 1. The Company out-licenses certain of its IP to other pharmaceutical companies in specific territories that allow the customer to use, develop, commercialize, or otherwise exploit the licensed IP. In accordance with Topic 606, the Company analyzes the contracts to identify its performance obligations within the contract. Most of the Company’s out-license arrangements contain multiple performance obligations and variable pricing. After the performance obligations are identified, the Company determines the transaction price, which generally includes upfront fees, milestone payments related to the achievement of developmental, regulatory, or commercial goals, and royalty payments on net sales of licensed products. The Company considers whether the transaction price is fixed or variable, and whether such is subject to return. Variable consideration is only included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. If any portion of the transaction price is constrained, it is excluded from the transaction price until the constraint no longer exists. The Company then allocates the transaction price to the performance obligation to which the consideration is related. Where a portion of the transaction price is received and allocated to continuing performance obligations under the terms of the arrangement, it is recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied. The Company’s contracts may contain one or multiple promises, including the license of IP and development services. The licensed IP is capable of being distinct from the other performance obligations identified in the contract and is distinct within the context of the contract, as upon transfer of the IP, the customer is able to use and benefit from it, and the customer could obtain the development services from other parties. The Company also considers the economic and regulatory characteristics of the licensed IP and other promises in the contract to determine if it is a distinct performance obligation. The Company considers if the IP is modified or enhanced by other performance obligations through the life of the agreement and whether the customer is contractually or practically required to use updated IP. The IP licensed by the Company has been determined to be functional IP. The IP is not modified during the license period and therefore, the Company recognizes revenues from any portion of the transaction price allocated to the licensed IP when the license is transferred to the customer and they can benefit from the right to use the IP. The Company recognized revenue allocated to the licensed IP performance obligation upon transfer of the license of $0.1 million and $30.0 million for the years ended December 31, 2019 and 2018, respectively. Other performance obligations included in most of the Company’s out-licensing agreements include performing development services to reach clinical and regulatory milestone events. The Company satisfies these performance obligations at a point-in-time, because the customer does not simultaneously receive and consume the benefits as the development occurs, the development does not create or enhance an asset controlled by the customer, and the development does not create an asset with no alternative use. The Company considers milestone payments to be variable consideration measured using the most likely amount method, as the entitlement to the consideration is contingent on the occurrence or nonoccurrence of future events. The Company allocates each variable milestone payment to the associated milestone performance obligation, as the variable payment relates directly to the Company’s efforts to satisfy the performance obligation and such allocation depicts the amount of consideration to which the Company expects to be entitled for satisfying the corresponding performance obligation. The Company re-evaluates the probability of achievement of such performance obligations and any related constraint, and adjusts its estimate of the transaction price as appropriate. To date, no amounts have been constrained in the initial or subsequent assessments of the transaction price. The Company recognized revenue allocated to development performance obligations upon transfer to the customer of $20.0 million and $2.0 million for the years ended December 31, 2019 and 2018, respectively. Certain out-license agreements include performance obligations to manufacture and provide drug product in the future for commercial sale when the licensed product is approved. For the commercial, sales-based royalties, the consideration is predominantly related to the licensed IP and is contingent on the customer’s subsequent sales to another commercial customer. Consequently, the sales- or usage-based royalty exception would apply. Revenue will be recognized for the commercial, sales-based milestones as the underlying sales occur. The Company exercises significant judgment when identifying distinct performance obligations within its out-license arrangements, determining the transaction price, which often includes both fixed and variable considerations, and allocating the transaction price to the proper performance obligation. The Company did not use any other significant judgments related to out-licensing revenue during the years ended December 31, 2019 and 2018. 2. Global Supply Chain Platform The Company’s Global Supply Chain Platform manufactures API for use internally in its research and development activities as well as its clinical studies, and for sale to pharmaceutical customers globally. The Company generates additional revenue on this platform, by providing small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies and selling pharmaceutical products under 503B regulations set forth by the FDA. Revenue earned by the Global Supply Platform is recognized when the Company has satisfied its performance obligation, which is the shipment or the delivery of drug products. The underlying contracts for these sales are generally purchase orders and the Company recognizes revenue at a point-in-time. Any remaining performance obligations related to product sales are the result of customer deposits and are reflected in the deferred revenue contract liability balance. 3. Commercial Platform The Company’s Commercial Platform generates revenue by distributing specialty products through independent pharmaceutical wholesalers. The wholesalers then sell to an end-user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end-user and the Company. Upon the sale by the wholesaler to the end-user, the wholesaler will chargeback the difference between the original list price and price at which the product was sold to the end-user. The Company also offers cash discounts, which approximate 2.3% of the gross sales price, as an incentive for prompt customer payment, and, consistent with industry practice, the Company’s return policy permits customers to return products within a window of time before and after the expiration of product dating. Further, the Company offers contractual allowances, generally rebates or administrative fees, to certain wholesale customers, group purchasing organizations (“GPOs”), and end-user customers, consistent with pharmaceutical industry practices. Revenues are recorded net of provisions for variable consideration, including discounts, rebates, GPO allowances, price adjustments, returns, chargebacks, promotional programs and other sales allowances. Accruals for these provisions are presented in the consolidated financial statements as reductions in determining net sales and as a contra asset in accounts receivable, net (if settled via credit) and other current liabilities (if paid in cash). As of December 31, 2019 and 2018, the Company’s total provision for chargebacks and other deductions included as a reduction of accounts receivable totaled $14.4 million and $13.1 million, respectively. The Company’s total provision for chargebacks and other revenue deductions was $87.2 million, $36.5 million, and $10.6 million for the years ended December 31, 2019, 2018, and 2017, respectively. The Company exercises significant judgment in its estimates of the variable transaction price at the time of the sale and recognizes revenue when the performance obligation is satisfied. Factors that determine the final net transaction price include chargebacks, fees for service, cash discounts, rebates, returns, warranties, and other factors. The Company estimates all of these variables based on historical data obtained from previous sales finalized with the end-user customer on a product-by-product basis. At the time of sale, revenue is recorded net of each of these deductions. Through the normal course of business, the wholesaler will sell the product to the end-user, determining the actual chargeback, return products, and take advantage of cash discounts, charge fees for services, and claim warranties on products. The final transaction price per product is compared to the initial estimated net sale price and reviewed for accuracy. The final prices and other factors are immediately included in the Company’s historical data from which it will estimate the transaction price for future sales. The underlying contracts for these sales are generally purchase orders including a single performance obligation, generally the shipment or delivery of products and the Company recognizes this revenue at a point-in-time. Disaggregation of revenue The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer (in thousands). For the Year Ended December 31, 2019 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 17,367 $ 50,427 $ 67,794 Spain 20,000 — — 20,000 Austria — 4,422 — 4,422 India — 3,066 — 3,066 China 562 1,543 — 2,105 United Kingdom — 1,023 — 1,023 Other Foreign Countries — 2,819 — 2,819 Total Revenue $ 20,562 $ 30,240 $ 50,427 $ 101,229 For the Year Ended December 31, 2018 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 7,478 $ 30,426 $ 37,904 Spain 30,000 — — 30,000 Austria — 9,569 — 9,569 China 2,776 1,640 — 4,416 India — 3,457 — 3,457 Other Foreign Countries — 3,754 — 3,754 Total Revenue $ 32,776 $ 25,898 $ 30,426 $ 89,100 For the Year Ended December 31, 2017 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 2,715 $ 17,218 $ 19,933 India — 8,479 — 8,479 Austria — 3,962 — 3,962 China 911 1,892 — 2,803 Taiwan 500 — — 500 Other Foreign Countries — 2,366 — 2,366 Total Revenue $ 1,411 $ 19,414 $ 17,218 $ 38,043 The Company also disaggregates its revenue by product group which can be found in Note 16 – Business Segment, Geographic, and Concentration Risk Information. Contract balances The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers (in thousands). December 31, 2019 2018 Accounts receivable, gross $ 31,207 $ 26,061 Chargebacks and other deductions (14,394 ) (13,101 ) Allowance for doubtful accounts (124 ) (9 ) Accounts receivable, net $ 16,689 $ 12,951 Deferred revenue 218 190 Total contract liabilities $ 218 $ 190 The following tables illustrate accounts receivable by reportable segments (in thousands). December 31, 2019 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 49 $ 1,522 $ 29,636 $ 31,207 Chargebacks and other deductions — (1 ) (14,393 ) (14,394 ) Allowance for doubtful accounts — (114 ) (10 ) (124 ) Accounts receivable, net $ 49 $ 1,407 $ 15,233 $ 16,689 December 31, 2018 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ — $ 7,814 $ 18,247 $ 26,061 Chargebacks and other deductions — — (13,101 ) (13,101 ) Allowance for doubtful accounts — (9 ) — (9 ) Accounts receivable, net $ — $ 7,805 $ 5,146 $ 12,951 As of December 31, 2019, $0.2 million of the deferred revenue balance relates to customer deposits made by customers of the Global Supply Chain Platform and is included within accrued expenses on the consolidated balance sheet. Upon delivery of certain drug product, the Company will recognize revenue of $0.2 million. Other amounts included within the deferred revenue balance are not material to the consolidated financial statements. As of December 31, 2018, the $0.2 million contract liability related to customer deposits made by customers of the Global Supply Chain Platform. The Company satisfied its performance obligations allocated to these contract liabilities during the year ended December 31, 2019 There were no other material changes to contract balances during the year ended December 31, 2019. During December 2019, the Company entered into an agreement to out-license three of its proprietary products and to grant an option, excercisable by the licensee, to license two additional product canididates on separately negotiated terms, under which the Company is entitled to receive an initial payment, regulatory and commercial milestone payments, and sales-based royalty payments. The Company determined that the contract included a distinct performance obligation to deliver a license of functional IP with the regulatory data necessary for the licensee to benefit from its right to use the IP. The Company is not required to provide any additional goods or services under the agreement. The Company determined that the initial payment is fixed consideration and the regulatory and commercial milestone payments and sales-based royalty payments are variable consideration; the regulatory milestone payments will be constrained until the Company determines that it is probable that the milestones will occur. The licensed IP is considered functional and therefore, the Company will recognize revenue at a point-in-time, when such performance obligation is satisfied. Revenue from the regulatory milestones will be recognized when the constraint on the related variable consideration is alleviated. As of December 31, 2019, the Company had not yet satisfied its performance obligation to deliver the licensed IP with the necessary regulatory data and therefore, no revenue was recorded under this contract during 2019. Practical expedients used During the adoption of ASC 606, the Company applied the practical expedient in paragraph 606-10-10-4, the Portfolio Approach The Company applies the optional exemption in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations related to the license of IP. This practical expedient is applied because the out-licensing agreements include sales-based royalties in exchange for the license of IP accounted for in accordance with Topic 606 and there is significant uncertainty surrounding the future variable consideration that could be received.

Selected Quarterly Financial Da

Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Data (Unaudited)	18 . The following tables present our unaudited quarterly results of operations for each quarter within the two most recent fiscal years. This unaudited quarterly information has been prepared on the same basis as our audited consolidated financial statements and, in the opinion of management, the statement of operations data includes all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the results of operations for these periods. The results of operations for any quarter are not necessarily indicative of the results of operations for any future periods. Fiscal 2019 Quarter Ended March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 (In thousands, except per share data) Statements of Operations Data: Revenue: Product sales $ 25,163 $ 22,033 $ 19,237 $ 14,102 License and other revenue 144 164 127 20,259 Total revenue 25,307 22,197 19,364 34,361 Costs and operating expenses: Costs of sales 19,902 16,942 17,071 15,704 Research and development expenses (2) 24,475 18,507 19,588 21,823 Selling, general, and administrative expenses 15,188 17,169 16,283 18,109 Total costs and operating expenses 59,565 52,618 52,942 55,636 Operating loss (34,258 ) (30,421 ) (33,578 ) (21,275 ) Net loss (36,230 ) (32,105 ) (34,787 ) (22,411 ) Less: net loss attributable to non-controlling interests (997 ) (74 ) (29 ) (684 ) Net loss attributable to Athenex, Inc. $ (35,233 ) $ (32,031 ) $ (34,758 ) $ (21,727 ) Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted $ (0.53 ) $ (0.44 ) $ (0.45 ) $ (0.28 ) Fiscal 2018 Quarter Ended March 31, 2018 June 30, 2018 September 30, 2018 December 31, 2018 (In thousands, except per share data) Statements of Operations Data: Revenue: Product sales $ 12,605 $ 11,471 $ 13,309 $ 19,009 License and other revenue 25,231 94 5,119 2,262 Total revenue 37,836 11,565 18,428 21,271 Costs and operating expenses: Costs of sales 11,326 9,443 11,965 14,271 Research and development expenses (2) 21,303 26,572 51,202 20,828 Selling, general, and administrative expenses 13,080 12,817 11,493 11,618 Total costs and operating expenses 45,709 48,832 74,660 46,717 Operating loss (7,873 ) (37,267 ) (56,232 ) (25,446 ) Net loss (7,339 ) (36,950 ) (57,260 ) (27,162 ) Less: net loss attributable to non-controlling interests (41 ) (91 ) (11,090 ) (49 ) Net loss attributable to Athenex, Inc. $ (7,298 ) $ (36,859 ) $ (46,170 ) $ (27,113 ) Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted $ (0.12 ) $ (0.58 ) $ (0.70 ) $ (0.41 )

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	19 . Rental and lease commitments In August 2015, the Company entered into a lease agreement with FSMC to occupy a portion of the Conventus Center for Collaborative Medicine in Buffalo, NY. A deferred rent liability for this agreement of $1.7 million was recorded as of December 31, 2018. Total rent expense related to this location, recognized on a straight-line basis, was $1.0 million for the each of the years ended December 31, 2019, 2018, and 2017. In July 2015, CDE entered into an agreement to lease facilities in Hong Kong. Under the rental agreement, CDE will make monthly payments of less than $0.1 million for three years beginning on July 1, 2015. Total rent expense related to this location, recognized on a straight-line basis, amounted to $0.3 million, $0.4 million, and $0.4 million for the years ended December 31, 2019, 2018, and 2017, respectively. The agreement expired in November 2019. In November 2019, CDE entered into an agreement to lease facilities in Hong Kong through November 2022. Rent expense is recognized on a straight-line basis and was not material to the financial statements for the year ended December 31, 2019. In October 2016, the Company’s Commercial Platform entered into an agreement to lease office space in Chicago, IL. Under the lease agreement, the Company will make monthly payments based on an escalating scale over ten years. Total rent expense related to this location, recognized on a straight-line basis, amounted to $0.3 million, $0.3 million, and less than $0.2 million for the years ended December 31, 2019, 2018, and 2017, respectively. A deferred rent liability for this agreement of $0.3 million was recorded as of December 31, 2018. In lieu of a security deposit, an irrevocable letter of credit was issued to the landlord in the amount of $0.3 million. The Company leases its manufacturing and office facilities in Chongqing, China, where it produces API and performs research and development. Rent expense is recognized on a straight-line basis and amounted to $0.6 million for each of the years ended December 31, 2019, 2018, and 2017. The Company entered into additional leases for lab space, warehouse facilities, and various equipment in, Houston, TX; Cranford, NJ; Taipei, Taiwan; Latin America; and Buffalo, NY, during 2018 and 2019 which expire at various times through 2026. Rent expense recognized for these operating leases was not material to the financial statements for the years ended December 31, 2019, 2018, and 2017. Future minimum payments under the non-cancelable operating leases consists of the following as of December 31, 2019 (in thousands): Year ending December 31: Minimum payments 2020 $ 3,229 2021 2,843 2022 2,623 2023 2,096 2024 2,002 Thereafter 1,950 $ 14,743 Commitments under New York State and Chongqing Partnerships Under its partnerships with New York State and CQ as described in Note 12 – Business and Economic Collaborative Arrangements Business and Economic Collaborative Agreements Legal Proceedings From time to time, the Company may become subject to other legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patent or other intellectual property rights. The Company is not currently a party to any other material legal proceedings, nor is it aware of any pending or threatened litigation that, in the Company’s opinion, would have a material adverse effect on the business, operating results, cash flows or financial condition should such litigation be resolved unfavorably.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	20 . SUBSEQUENT EVENTS In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China. The spread of this virus has caused business disruption beginning in January 2020. The outbreak has temporarily delayed the Company’s planned operations of its new API Plant in Chongqing, China and may disrupt the supply of API for the Company’s clinical trials that are currently provided by its existing API plant also located in Chongqing, China. While the business disruption is currently expected to be temporary, there is uncertainty around the duration of these disruptions or the possibility of other effects on the business. The disruption may have a material adverse impact on the Company’s business, financial condition, and results of operations.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2019
Valuation And Qualifying Accounts [Abstract]
Schedule of Valuation and Qualifying Accounts	Activity in the following valuation and qualifying accounts consisted of the following (in thousands): Col. C - Additions Col. A Description Col. B Balance at Beginning of Period Charged to Costs & Expenses Charged to Other Accounts - Describe Col. D Deductions - Describe Col. E Balance at End of Period December 31, 2019 Allowance for doubtful accounts $ 9 $ 488 (1) $ — $ (373 ) (1) $ 124 Allowance for chargebacks and other deductions $ 13,101 $ 95,100 (2) $ — $ (93,807 ) (2) $ 14,394 Deferred tax asset valuation allowance $ 88,455 $ — $ 32,350 (3) $ — $ 120,805 December 31, 2018 Allowance for doubtful accounts $ 84 $ 28 (1) $ — $ (103 ) (1) $ 9 Allowance for chargebacks and other deductions $ 3,711 $ 36,102 (2) $ — $ (26,712 ) (2) $ 13,101 Deferred tax asset valuation allowance $ 60,379 $ — $ 28,076 (3) $ — $ 88,455 December 31, 2017 Allowance for doubtful accounts $ 155 $ 662 (1) $ — $ (733 ) (1) $ 84 Allowance for chargebacks and other deductions $ — $ 3,834 (2) $ — $ (123 ) (2) $ 3,711 Deferred tax asset valuation allowance $ 62,308 $ — $ (1,929 ) (3) $ — $ 60,379 (1) Increases in the allowance for doubtful accounts consist of our provision for bad debts, which is included within selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss. Decreases in the allowances for doubtful accounts consist of the write-off of specific accounts and the recovery of previously reserved receivables. (2) Increases in the allowance for chargebacks and other deductions consist of our provision for chargebacks, cash discounts, returns, fees, and other credits, which are a deduction from product sales on the consolidated statements of operations and comprehensive loss. Decreases in the allowances for chargebacks and other deduction consist of the collection of the underlying accounts and advances received on chargebacks. ( 3 ) Increases and decreases in the valuation allowance for deferred income tax assets offset the increases and decreases in our gross deferred tax assets, based on the expected realization of those future tax benefits.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, measurement of acquired assets and assumed liabilities in business combinations, allowance for doubtful accounts, inventory reserves, the valuation of the derivative liability, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates.
Functional Currency	Functional Currency Assets and liabilities of subsidiaries that prepare financial statements in currencies other than the U.S. dollar are translated using rates of exchange as of the balance sheet date and the statements of operations and comprehensive loss are translated at the average rates of exchange for each reporting period. The Company recorded a foreign currency translation loss in accumulated other comprehensive loss of $0.1 million for the year ended December 31, 2019, a loss of $0.5 million for the year ended December 31, 2018 and a gain of $1.2 million for the year ended December 31, 2017.
Cash, Cash Equivalents, and Marketable Securities	Cash, Cash Equivalents, and Marketable Securities The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, money market accounts, as well as certificates of deposit. Funds held in foreign accounts that are subject to regulations governing transfers oversees are included within cash and cash equivalents. As of December 31, 2019 and 2018, the Company had $7.6 million and $3.2 million, respectively, at its Chinese subsidiaries, which were subject to Chinese funds transfer limitations. The Company generally does not enter into investments for trading or speculative purposes, rather to preserve its capital for the purpose of funding operations.
Accounts Receivable, net	Accounts Receivable, net Accounts receivable are recorded at the invoiced amount. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance for doubtful accounts, based upon a history of past write-offs, the age of the receivables, and current credit conditions.
Inventories	Inventories Inventories for clinical trials are stated at the lower of cost and net realizable value, with approximate cost being determined on a first-in-first-out basis. Active pharmaceutical ingredient (“API”) inventory is stated at the lower of cost and net realizable value, with approximate cost being determined on a weighted average basis. The Company provides inventory write-downs based on excess and obsolete inventories determined primarily by future demand forecasts. The write-down is measured as the difference between the cost of the inventory and market, based upon assumptions about future demand, and is charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis.
Property and Equipment, net	Property and Equipment, net Property and equipment are recorded at cost or acquisition date fair value in a business acquisition. Depreciation is recorded over the estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the consolidated balance sheets and the resulting gain or loss is recorded to general and administrative expense in the consolidated statements of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred. Estimated useful lives for property and equipment are as follows: Property and Equipment Estimated Useful Life Land Not depreciated Equipment 5 - 8 years Furniture and fixtures 5 years Computer hardware 3 years Leasehold improvements Lesser of estimated useful life or remaining lease term Construction in process Not depreciated
Leases	Leases On January 1, 2019, the Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) The lease liabilities are determined as the present value of future fixed minimum lease payments. In determining the discount rate, the Company uses rates implicit in the lease, or if not readily available, the Company uses an estimated incremental borrowing rate based on yield trends in the biotechnology and healthcare industry and debt instruments held by the Company with stated interest rates. The Company uses the stated rate per lease agreement in determining the finance lease liabilities. The lease term is determined at the commencement date and considers whether it is reasonably certain that the Company will exercise renewal options or termination options. The lease liabilities and ROU asset are amortized over the term of the lease with operating lease expenses being recognized on a straight-line basis over the lease terms. The Company elected the practical expedients permitted under Topic 842, which allows it to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for short-term leases. See Note 10— Debt and Lease Obligations. Prior period amounts continue to be reported in accordance with our historic accounting under previous lease guidance, ASC 840, Leases Topic 840 ( Topic 840 Recent Accounting Pronouncements
Fair Value of Financial Instruments	Fair Value of Financial Instruments Financial instruments consist of cash and cash equivalents, short-term investments, marketable securities, an investment, accounts receivable, accounts payable, accrued liabilities, contingent consideration, and long-term debt. Cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities, contingent consideration, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts.
Business Acquisitions	Business Acquisitions The Company accounts for acquired businesses using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Identifiable amortizing intangible assets are recorded on the consolidated balance sheet at fair value and amortized over their estimated useful lives. Acquisition-related costs are expensed as incurred. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill.
Goodwill	Goodwill The Company tests goodwill for impairment annually on October 1 st
Intangible Assets, net	Intangible Assets, net Intangible assets arising from a business acquisition are recognized at fair value as of the acquisition date. The Company amortizes intangible assets using the straight-line method. When the straight-line method of amortization is utilized, the estimated useful life of the intangible asset is shortened to assure the recognition of amortization expense corresponds with the expected cash flows. Other purchased intangibles, including certain licenses, are capitalized at cost and amortized on a straight-line basis over the license life, when a future economic benefit is probable and measurable. If a future economic benefit is not probable or measurable, the license costs are expensed as incurred within research and development expenses.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Goodwill and Intangible Assets, net
Treasury Stock	Treasury Stock The Company records treasury stock activities at the cost of the acquired stock. The Company’s accounting policy upon the formal retirement of treasury stock is to deduct the par value from common stock and to reflect any excess of cost over par value as a reduction to additional paid-in capital (to the extent created by previous issuances of the stock) and then accumulated deficit.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted Accounting Standards Codification (“ASC”), Topic 606, “ Revenue from Contracts with Customers Revenue Recognition
Research and Development Expenses	Research and Development Expenses Costs for research and development (“R&D”) of products, including payroll, contractor expenses, and supplies, are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the obligations are recorded when the milestone results are probable of being achieved.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Changes in unrealized gains and losses on investments and foreign currency translation adjustments represent the differences between the Company’s net loss and comprehensive loss.
Stock-Based Compensation	Stock-Based Compensation Awards granted to employees The Company recognizes stock-based compensation based on the grant date fair value of stock options granted to employees, officers, and directors. The Company used the Black-Scholes option pricing model to calculate the grant date fair value of stock options. The Black-Scholes option pricing model requires inputs for risk-free interest rate, dividend yield, volatility, fair value of common stock, and expected lives of the stock options. The risk-free rate for periods within the expected life of the stock option is based on the U.S. Treasury yield curve in effect at the time of the grant. No dividend yield is used, consistent with the Company’s history. Expected volatility is based on historical volatilities of the stock prices of peer biopharmaceutical companies. The fair value of common stock is based on the quoted market price of the Company’s common stock on grant date. The Company uses the simplified method for determining the expected lives of stock options. The Company recognizes compensation expenses based on the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting period. Stock grants The Company grants common stock to key officers and directors and records the fair value of these grants, based on the fair value of the common stock on the grant date, as compensation expense throughout the requisite service period.
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred income tax expense or benefit is the result of changes in the deferred income tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred income tax assets where, based upon the available evidence, management concludes that it is more-likely-than not that the deferred income tax assets will not be realized. In evaluating its ability to recover deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of the deferred income tax assets, the Company has recorded a valuation allowance against its deferred income tax assets. Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more likely than not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in income tax expense (benefit); however, the Company currently has no interest or penalties related to income taxes.
Segment and Geographic Information	Segment and Geographic Information The Company’s chief operating decision-maker, its Chief Executive Officer, reviews its operating results on an aggregate basis and at the operating segment level for purposes of allocating resources and evaluating financial performance. The Company has three business platforms which are the operating segments: (1) Oncology Innovation Platform, for the discovery and development of cancer supportive therapies, (2) Commercial Platform, the manufacturing and selling of commercial pharmaceutical products, and (3) Global Supply Chain Platform, the cGMP manufacturing and marketing of API, and clinical products. Each operating segment has a segment manager who is held accountable for operations and operating results. Accordingly, the Company operates in three reportable segments.
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and certificates of deposit and invests in highly liquid U.S. treasury notes, commercial paper, and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility, and research and development facility in China, and therefore is subject to foreign currency fluctuation and regulatory uncertainties.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, " Leases (Topic 842), The Company adopted the new lease standard on January 1, 2019 and used the effective date as the date of initial application. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which allowed the Company (1) to not reassess whether any expired or existing contracts are or contain leases, (2) to not reassess the lease classification for any expired or existing leases, and (3) to not reassess initial direct costs for any existing leases. The Company also elected the single component practical expedient, which requires the Company, by class of underlying asset, not to allocate the total consideration to the lease and nonlease components based on their relative stand-alone selling prices. This single component practical expedient requires the Company to account for the lease component and nonlease component(s) associated with that lease as a single component if (i) the timing and pattern of transfer of the lease component and the nonlease component(s) associated with it are the same and (ii) the lease component would be classified as an operating lease if it were accounted for separately. In preparation for adoption of the standard and to assess the ongoing impact of the standard, the Company implemented internal controls to enable the preparation of financial information. The standard had a significant impact on the consolidated balance sheet, with no significant impact on its consolidated statement of operations and comprehensive loss. On the adoption date, the Company recognized $9.8 million of operating lease ROU assets, $11.9 million of operating lease liabilities, and derecognized its existing deferred rent balance of $2.1 million. The new standard provides a number of optional practical expedients in transition. The Company has elected the package of practical expedients permitted under the transition guidance within the new standard, which allows the Company (1) to not reassess whether any expired or existing contracts are or contain leases, (2) to not reassess the lease classification for any expired or existing leases, and (3) to not reassess initial direct costs for any existing leases In preparation for adoption of the standard, the Company has implemented internal controls to enable the preparation of financial information. Further, the Company has made an accounting policy election to keep leases with an initial term of twelve months or less off the balance sheet. The Company recognizes those lease payments in the consolidated statement of operations and comprehensive loss over the lease term. See Note 10— Debt and Lease Obligations Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, “ Measurement of Credit Losses on Financial Instruments”

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Property, Plant and Equipment, Useful Life	Estimated useful lives for property and equipment are as follows: Property and Equipment Estimated Useful Life Land Not depreciated Equipment 5 - 8 years Furniture and fixtures 5 years Computer hardware 3 years Leasehold improvements Lesser of estimated useful life or remaining lease term Construction in process Not depreciated

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands): December 31, 2019 2018 Raw materials and purchased parts $ 4,176 $ 4,092 Work in progress 1,870 3,166 Finished goods 26,584 21,529 Total inventories $ 32,630 $ 28,787

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property and equipment, net, consists of the following (in thousands): December 31, 2019 2018 Land $ 1,117 $ 1,132 Equipment 6,724 6,236 Furniture and fixtures 578 640 Computer hardware 3,142 2,118 Leasehold improvements 2,792 1,380 Construction in process 14,758 3,826 Property and equipment, gross 29,111 15,332 Less: accumulated depreciation (5,958 ) (3,885 ) Property and equipment, net $ 23,153 $ 11,447

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill for each Reporting Unit	The changes in the carrying amount of goodwill for each reporting unit to which goodwill is assigned for the periods indicated are as follows (in thousands): Global Supply Chain Oncology Innovation Platform Total Balance as of January 1, 2018 $ 26,510 $ 11,285 $ 37,795 Effect of currency translation adjustment (277 ) (23 ) (300 ) Balance as of December 31, 2018 26,233 11,262 37,495 Goodwill acquired — 1,018 1,018 Effect of currency translation adjustment (64 ) 64 — Balance as of December 31, 2019 $ 26,169 $ 12,344 $ 38,513
Summary of Identifiable Intangible Asset, Net	The Company’s identifiable intangible assets, net, consist of the following (in thousands): December 31, 2019 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 8,935 $ 3,561 $ — $ 5,374 Polymed customer list 1,593 1,164 — 429 Polymed technology 3,712 1,297 — 2,415 Product rights 530 360 170 — Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 728 — — 728 Effect of currency translation adjustment (424 ) — — (424 ) Total intangibles, net $ 15,074 $ 6,382 $ 170 $ 8,522 December 31, 2018 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 8,935 $ 2,060 $ — $ 6,875 Polymed customer list 1,593 938 — 655 Polymed technology 3,712 999 — 2,713 Product rights 530 263 — 267 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,026 — 298 728 Effect of currency translation adjustment (390 ) — — (390 ) Total intangibles, net $ 15,406 $ 4,260 $ 298 $ 10,848
Schedule of Expected Amortization Expense of Finite-Lived Intangible Assets	The Company expects amortization expense related to its finite-lived intangible assets for the next 5 years and thereafter to be as follows as of December 31, 2019 (in thousands): Year ending December 31: Estimated Amortization Expense 2020 $ 2,138 2021 1,782 2022 1,011 2023 982 2024 941 Thereafter 1,364 $ 8,218

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at December 31, 2019 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 5,460 $ 5,460 $ — $ — Short-term investments - certificates of deposit 15,110 — 15,110 — Short-term investments - commercial paper 51,017 — 51,017 — Financial assets included within short-term investments Short-term investments - certificates of deposit 10,054 — 10,054 — Short-term investments - commercial paper 22,835 — 22,835 — Available-for-sale investment 250 250 — — Total assets $ 104,726 $ 5,710 $ 99,016 $ — Fair Value Measurements at December 31, 2018 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Financial assets included within cash and cash equivalents Money market funds $ 25 $ 25 $ — $ — Short-term investments - commercial paper 5,396 — 5,396 — Financial assets included within short-term investments Short-term investments - commercial paper 36,544 — 36,544 — Short-term investments - corporate notes 16,699 — 16,699 — Short-term investments - U.S. government bonds 3,998 — 3,998 — Available-for-sale investment 388 388 — — Total assets $ 63,050 $ 413 $ 62,637 $ —

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): December 31, 2019 2018 Accrued wages and benefits $ 7,541 $ 5,061 Accrued clinical expenses 2,510 2,653 Accrued operating expenses 1,885 8,128 Deferred revenue 218 190 Accrued R&D licensing fees 384 4,827 Accrued inventory purchases 7,194 — Accrued tax withholdings 187 — Accrued selling fees and rebates 1,577 423 Accrued construction costs 22,811 16,436 Total accrued expenses $ 44,307 $ 37,718

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Components of Loss Before Income Tax Expense	The components of loss before income tax expense consist of the following (in thousands): Year Ended December 31, 2019 2018 2017 Domestic $ (109,769 ) $ (95,479 ) $ (125,770 ) Foreign (14,836 ) (33,132 ) (5,541 ) $ (124,605 ) $ (128,611 ) $ (131,311 )
Components of the Income Tax Expense	The components of the income tax expense consist of the following (in thousands): Year Ended December 31, 2019 2018 2017 Current: Federal $ — $ — $ 64 State 23 27 (92 ) Foreign 419 455 440 442 482 412 Deferred: Federal (26,878 ) (26,260 ) (3,222 ) State (2,567 ) (293 ) 5,799 Foreign (2,411 ) (1,863 ) (874 ) (31,856 ) (28,416 ) 1,703 Change in valuation allowance 32,342 28,034 (2,030 ) $ 928 $ 100 $ 85
Schedule of Income Tax Expense Differs From the Federal Statutory Rate	The income tax expense differs from the federal statutory rate due to the following: Year Ended December 31, 2019 2018 2017 Statutory rate 21.0 % 21.0 % 34.0 % State taxes, net of federal benefit 2.0 0.2 (4.3 ) Foreign rate differential 0.1 (0.3 ) (0.6 ) Federal income tax rate change — — (25.9 ) Valuation allowance (25.9 ) (21.6 ) 1.5 Other 2.1 0.6 (4.8 ) (0.7 )% (0.1 )% (0.1 )%
Schedule of Net Deferred Income Tax Assets	Net deferred income tax assets consist of the following (in thousands): December 31, 2019 2018 Intangible assets $ 11,348 $ 10,273 Property and equipment 77 238 Stock-based compensation 9,551 7,508 Net operating loss carryforwards 81,630 60,362 Tax credit carryforwards 9,191 5,341 Research and development deduction 1,493 - Reserves and accruals 8,377 6,141 Gross deferred income tax assets 121,667 89,863 Less: valuation allowance (120,805 ) (88,455 ) Net deferred income tax assets 862 1,408 Intangible assets (862 ) (922 ) Gross deferred income tax liabilities (862 ) (922 ) Net deferred income tax assets $ — $ 486

Debt and Lease Obligations (Tab

Debt and Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2019
Debt And Lease Obligations [Abstract]
Schedule of Debt	The Company’s debt as of December 31, 2019 and 2018, consists of the following (in thousands): December 31, 2019 2018 Current portion of mortgage $ 686 $ 779 Current portion of finance and capital lease obligations 194 182 Current portion of operating lease obligations 3,010 — Long-term portion of finance and capital lease obligations 227 422 Long-term portion of operating lease obligations 7,620 — Chongqing Maliu credit agreement 5,731 — Senior secured loan, net of debt discount and financing fees of $3,592 and $4,619, respectively 46,408 45,381 Total $ 63,876 $ 46,764
Summary of Components of Lease Expense	The components of lease expense are as follows (in thousands): Year Ended December 31, 2019 Operating lease cost $ 3,162 Finance lease cost: Amortization of assets 81 Interest on lease liabilities 31 Total net lease cost $ 3,274
Schedule of Supplemental Balance Sheet Information Related to Leases of Debt	Supplemental balance sheet information related to leases is as follows (in thousands, except lease term and discount rate): December 31, 2019 Finance leases: Property and equipment, at cost $ 688 Accumulated amortization, net (109 ) Property and equipment, net $ 579 Current obligations of finance leases $ 194 Long-term portion of finance leases 227 Total finance lease obligations $ 421 Weighted average remaining lease term (in years): Operating leases 5.21 Finance leases 2.11 Weighted average discount rate: Operating leases 12.9 % Finance leases 5.9 %
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases is as follows (in thousands): Year Ended December 31, 2019 Cash paid for amount included in the measurements of lease liabilities: Operating cash flows from operating leases $ 3,374 Operating cash flows from finance leases 31 Financing cash flows from finance leases 183 ROU assets recognized in exchange for new operating lease obligations $ 1,305
Schedule of Future Minimum Payments and Maturities of Leases	Future minimum payments and maturities of leases is as follows (in thousands): Year ending December 31: Operating Leases Finance Leases 2020 $ 3,229 $ 214 2021 2,843 214 2022 2,623 21 2023 2,096 — 2024 2,002 — Thereafter 1,950 — Total lease payments 14,743 449 Less: Imputed interest (4,113 ) (28 ) Total lease obligations 10,630 421 Less: Current obligations (3,010 ) (194 ) Long-term lease obligations $ 7,620 $ 227

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	The following table summarizes the status of the Company’s stock option activity granted under the Plans and 2017 Plans to employees, directors, and consultants (in thousands, except stock option amounts): Stock Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2018 10,687,650 $ 8.51 6.87 $ 44,688 Granted 875,000 13.14 — Exercised (331,779 ) 5.86 — Forfeited (165,488 ) 13.95 — Expired (148,447 ) 8.51 — Outstanding at December 31, 2019 10,916,936 $ 8.88 5.68 $ 69,785 Vested and exercisable at December 31, 2019 8,292,953 $ 7.19 4.90 $ 67,012
Schedule of Weighted-Average Assumptions Used as Inputs to Black-Scholes Option Pricing Model	The Company determines the fair value of stock option awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding a number of highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes option pricing model during the periods indicated: Year Ended December 31, 2019 2018 2017 Weighted average grant date fair value $ 8.06 $ 9.80 $ 7.01 Expected dividend yield — % — % — % Expected stock price volatility 64 % 59 % 66 % Risk-free interest rate 2.60 % 2.61 % 1.74 % Expected life of options (in years) 6.3 6.1 6.2
Schedule of Stock-Based Compensation Cost	The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the years ended December 31, 2019, 2018, and 2017 (in thousands): Year Ended December 31, 2019 2018 2017 Stock options $ 7,887 $ 9,786 $ 8,031 Restricted stock expense 566 1,008 2,160 Stock awarded to directors and officers 1,105 — 4,400 Employee stock purchase plan 327 217 — Total stock-based compensation expense $ 9,885 $ 11,011 $ 14,591 Cost of sales $ 248 $ 228 $ 137 Research and development expenses 3,251 2,621 2,030 Selling, general, and administrative expenses 6,386 8,162 12,424 Total stock-based compensation expense $ 9,885 $ 11,011 $ 14,591

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule Weighted Average Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share	The following weighted average outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable Athenex, Inc. to common stockholders for the periods presented because including them would have been antidilutive: Year Ended December 31, 2019 2018 2017 Stock options and other common stock equivalents 10,814,635 10,480,084 9,534,658 Unvested restricted common shares 45,581 113,260 393,408 Total potential dilutive common shares 10,860,216 10,593,344 9,928,066

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Schedule of Components and Changes of Accumulated Other Comprehensive Loss	The components and changes of accumulated other comprehensive loss, net of related income tax effects, are as follows (in thousands): Balance as of January 1, 2017 $ (1,304 ) Foreign currency translation adjustment 1,184 Unrealized loss on investment (26 ) Balance as of December 31, 2017 (146 ) Foreign currency translation adjustment (525 ) Unrealized loss on investment 15 Balance as of December 31, 2018 (656 ) Foreign currency translation adjustment 118 Unrealized gain on investment (97 ) Balance as of December 31, 2019 $ (635 )

Business Segment, Geographic,_2

Business Segment, Geographic, and Concentration Risk Information (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Summary of Revenue by Segments	Segment information is as follows (in thousands): Year Ended December 31, 2019 2018 2017 Total revenue: Oncology Innovation Platform $ 20,562 $ 32,776 $ 1,411 Global Supply Chain Platform 33,970 31,274 28,427 Commercial Platform 50,427 30,426 17,218 Total revenue for reportable segments 104,959 94,476 47,056 Intersegment revenue (3,730 ) (5,376 ) (9,013 ) Total consolidated revenue $ 101,229 $ 89,100 $ 38,043
Summary of Revenue by Product Group	Year Ended December 31, 2019 2018 2017 Total revenue by product group: API sales $ 12,733 $ 17,952 $ 15,351 Medical device sales — 2,344 1,747 Contract manufacturing revenue 391 458 1,360 Commercial product sales 67,411 35,640 17,648 License fees 20,100 32,000 750 Consulting 396 387 355 Grant revenue 198 319 832 Total consolidated revenue $ 101,229 $ 89,100 $ 38,043
Summary of Segment Information	Year Ended December 31, 2019 2018 2017 Net loss attributable to Athenex, Inc.: Oncology Innovation Platform $ (100,919 ) $ (89,912 ) $ (108,563 ) Global Supply Chain Platform (8,575 ) (16,858 ) (7,179 ) Commercial Platform (14,255 ) (10,670 ) (15,428 ) Total consolidated net loss attributable to Athenex, Inc. $ (123,749 ) $ (117,440 ) $ (131,170 )
Summary of Depreciation, Amortization and Assets by Segment	Year Ended December 31, 2019 2018 2017 Total depreciation and amortization Oncology Innovation Platform $ 762 $ 690 $ 482 Global Supply Chain Platform 1,489 1,603 2,272 Commercial Platform 1,566 976 919 Total consolidated depreciation and amortization $ 3,817 $ 3,269 $ 3,673 December 31, 2019 2018 Total assets: Oncology Innovation Platform $ 194,183 $ 135,878 Global Supply Chain Platform 63,598 58,816 Commercial Platform 52,151 36,401 Total assets $ 309,932 $ 231,095
Summary of Revenue by Geographical Segment	Year Ended December 31, 2019 2018 2017 Total revenue United States $ 67,794 $ 37,904 $ 19,933 Spain 20,000 30,000 — Austria 4,422 9,569 3,962 India 3,066 3,457 8,479 China 2,105 4,416 2,803 United Kingdom 1,023 — — Taiwan — — 500 Other foreign countries 2,819 3,754 2,366 Total consolidated revenue $ 101,229 $ 89,100 $ 38,043
Summary of Property and Equipment by Geographical Segment	December 31, 2019 2018 Total property and equipment, net: United States $ 11,486 $ 6,549 China 11,667 4,898 Total property and equipment, net $ 23,153 $ 11,447
Summary of Customer Revenue and Accounts Receivable Concentration	Customer revenue and accounts receivable concentration amounted to the following for the identified periods: Year Ended December 31, 2019 2018 2017 Percentage of total revenue by customer: Customer A 20 % 34 % — Customer B 16 % 12 % 15 % Customer C 15 % 9 % 6 % Customer D 14 % 9 % 7 % Customer E 4 % 4 % 19 % December 31, 2019 2018 Percentage of total accounts receivable by customer: Customer A 45 % 18 % Customer B 31 % 16 % Customer C 10 % — Customer D — 12 %

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2019
Revenue From Contract With Customer [Abstract]
Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer	Disaggregation of revenue The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer (in thousands). For the Year Ended December 31, 2019 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 17,367 $ 50,427 $ 67,794 Spain 20,000 — — 20,000 Austria — 4,422 — 4,422 India — 3,066 — 3,066 China 562 1,543 — 2,105 United Kingdom — 1,023 — 1,023 Other Foreign Countries — 2,819 — 2,819 Total Revenue $ 20,562 $ 30,240 $ 50,427 $ 101,229 For the Year Ended December 31, 2018 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 7,478 $ 30,426 $ 37,904 Spain 30,000 — — 30,000 Austria — 9,569 — 9,569 China 2,776 1,640 — 4,416 India — 3,457 — 3,457 Other Foreign Countries — 3,754 — 3,754 Total Revenue $ 32,776 $ 25,898 $ 30,426 $ 89,100 For the Year Ended December 31, 2017 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 2,715 $ 17,218 $ 19,933 India — 8,479 — 8,479 Austria — 3,962 — 3,962 China 911 1,892 — 2,803 Taiwan 500 — — 500 Other Foreign Countries — 2,366 — 2,366 Total Revenue $ 1,411 $ 19,414 $ 17,218 $ 38,043
Summary of Receivables and Contract Liabilities From Contracts with Customers	The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers (in thousands). December 31, 2019 2018 Accounts receivable, gross $ 31,207 $ 26,061 Chargebacks and other deductions (14,394 ) (13,101 ) Allowance for doubtful accounts (124 ) (9 ) Accounts receivable, net $ 16,689 $ 12,951 Deferred revenue 218 190 Total contract liabilities $ 218 $ 190
Summary of Accounts Receivable by Reportable Segments	The following tables illustrate accounts receivable by reportable segments (in thousands). December 31, 2019 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 49 $ 1,522 $ 29,636 $ 31,207 Chargebacks and other deductions — (1 ) (14,393 ) (14,394 ) Allowance for doubtful accounts — (114 ) (10 ) (124 ) Accounts receivable, net $ 49 $ 1,407 $ 15,233 $ 16,689 December 31, 2018 Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ — $ 7,814 $ 18,247 $ 26,061 Chargebacks and other deductions — — (13,101 ) (13,101 ) Allowance for doubtful accounts — (9 ) — (9 ) Accounts receivable, net $ — $ 7,805 $ 5,146 $ 12,951

Selected Quarterly Financial _2

Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Schedule of Unaudited Quarterly Results of Operations	The following tables present our unaudited quarterly results of operations for each quarter within the two most recent fiscal years. This unaudited quarterly information has been prepared on the same basis as our audited consolidated financial statements and, in the opinion of management, the statement of operations data includes all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the results of operations for these periods. The results of operations for any quarter are not necessarily indicative of the results of operations for any future periods. Fiscal 2019 Quarter Ended March 31, 2019 June 30, 2019 September 30, 2019 December 31, 2019 (In thousands, except per share data) Statements of Operations Data: Revenue: Product sales $ 25,163 $ 22,033 $ 19,237 $ 14,102 License and other revenue 144 164 127 20,259 Total revenue 25,307 22,197 19,364 34,361 Costs and operating expenses: Costs of sales 19,902 16,942 17,071 15,704 Research and development expenses (2) 24,475 18,507 19,588 21,823 Selling, general, and administrative expenses 15,188 17,169 16,283 18,109 Total costs and operating expenses 59,565 52,618 52,942 55,636 Operating loss (34,258 ) (30,421 ) (33,578 ) (21,275 ) Net loss (36,230 ) (32,105 ) (34,787 ) (22,411 ) Less: net loss attributable to non-controlling interests (997 ) (74 ) (29 ) (684 ) Net loss attributable to Athenex, Inc. $ (35,233 ) $ (32,031 ) $ (34,758 ) $ (21,727 ) Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted $ (0.53 ) $ (0.44 ) $ (0.45 ) $ (0.28 ) Fiscal 2018 Quarter Ended March 31, 2018 June 30, 2018 September 30, 2018 December 31, 2018 (In thousands, except per share data) Statements of Operations Data: Revenue: Product sales $ 12,605 $ 11,471 $ 13,309 $ 19,009 License and other revenue 25,231 94 5,119 2,262 Total revenue 37,836 11,565 18,428 21,271 Costs and operating expenses: Costs of sales 11,326 9,443 11,965 14,271 Research and development expenses (2) 21,303 26,572 51,202 20,828 Selling, general, and administrative expenses 13,080 12,817 11,493 11,618 Total costs and operating expenses 45,709 48,832 74,660 46,717 Operating loss (7,873 ) (37,267 ) (56,232 ) (25,446 ) Net loss (7,339 ) (36,950 ) (57,260 ) (27,162 ) Less: net loss attributable to non-controlling interests (41 ) (91 ) (11,090 ) (49 ) Net loss attributable to Athenex, Inc. $ (7,298 ) $ (36,859 ) $ (46,170 ) $ (27,113 ) Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted $ (0.12 ) $ (0.58 ) $ (0.70 ) $ (0.41 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments Under Non-Cancelable Leases	Future minimum payments under the non-cancelable operating leases consists of the following as of December 31, 2019 (in thousands): Year ending December 31: Minimum payments 2020 $ 3,229 2021 2,843 2022 2,623 2023 2,096 2024 2,002 Thereafter 1,950 $ 14,743

Company and Nature of Business

Company and Nature of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Dec. 09, 2019	May 07, 2019	Jul. 03, 2018	Sep. 29, 2017	Jun. 14, 2017	Jun. 13, 2017	Feb. 28, 2018	Jan. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Subsidiary Or Equity Method Investee [Line Items]
Aggregate net proceeds from stock issuance									$ 161,080	$ 123,134	$ 75,900
Sale of common stock									159,977	117,616	64,194
Private placement closing date	Dec. 9, 2019	May 7, 2019
Payments for offering expenses									1,103	5,518	$ 10,168
Accumulated deficit									567,465	$ 443,716
Cash, cash equivalents and short-term investments									$ 160,800
Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Warrants to purchase common stock outstanding			425,000
Warrants to purchase common stock, share price			$ 18.66
Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold			2,679,528
Common stock share price			$ 18.66
Gross proceeds from debt and equity financing			$ 100,000
Aggregate net proceeds of debt and equity financing, net of fees and offering expenses			97,100
Sale of common stock			50,000
Senior Secured Loan | Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Convertible bonds, aggregate principal value			$ 50,000
Debt instrument maturity term			5 years
LIBOR | Senior Secured Loan | Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Debt variable rate basis floor			2.00%
Basis spread on variable rate			9.00%
Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Convertible bonds, aggregate principal value				$ 7,000	$ 68,000
Convertible bonds, carrying value					$ 55,800
Common stock discount rate				20.00%
Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold									14,006,575	7,486,261	6,900,000
Aggregate cash proceeds net of underwriting discounts and commissions and offering costs						$ 64,200
Underwriting discounts and commissions						6,100
Offering costs						$ 5,600
Sale of common stock									$ 14	$ 7	$ 7
Common Stock | Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Shares issued upon conversion				795,455	7,727,273
IPO
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold						6,900,000
IPO | Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price						$ 11
IPO | Common Stock | Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price				$ 11
Underwriters
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold								4,300,000
Common stock share price							$ 15.25	$ 15.25
Number of days granted to underwriters option to purchase additional shares								30 days
Number of additional common stock shares purchase							465,000	645,000
Aggregate net proceeds from stock issuance							$ 68,100
Underwriting discounts and commissions and offering expenses							$ 4,600
Private Placement
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price	$ 15.30	$ 10
Net proceeds from issuance of private placement	$ 59,400	$ 99,900
Payments for offering expenses	$ 1,000	$ 100
Private Placement | Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Number of shares issued and sold	3,945,750	10,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019USD ($)SegmentReporting_Unit	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 01, 2019USD ($)
Summary Of Significant Accounting Policies [Line Items]
Foreign currency translation adjustment, net of income taxes	$ 118,000	$ (525,000)	$ 1,184,000
Number of operating segments | Segment	3
Number of reportable segments | Segment	3
Goodwill, impairment loss	$ 0	0	0
Number of reporting units | Reporting_Unit	2
Impairment of long-lived assets held-for-use	$ 200,000	$ 300,000	$ 100,000
Expected dividend yield	0.00%	0.00%	0.00%
Interest or penalties related to income taxes	$ 0
Operating lease ROU assets	8,818,000			$ 9,800,000
Operating lease liabilities	10,630,000			11,900,000
Deferred rent balance derecognized				$ 2,100,000
Chinese Subsidiaries
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents, funds transfer limitations	$ 7,600,000	$ 3,200,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Property, Plant and Equipment, Useful Life (Detail)	12 Months Ended
	Dec. 31, 2019
Land
Property, Plant and Equipment [Line Items]
Property and Equipment, Estimated Useful Life	Not depreciated
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and Equipment, Estimated Useful Life	5 years
Computer hardware
Property, Plant and Equipment [Line Items]
Property and Equipment, Estimated Useful Life	3 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and Equipment, Estimated Useful Life	Lesser of estimated useful life or remaining lease term
Construction in process
Property, Plant and Equipment [Line Items]
Property and Equipment, Estimated Useful Life	Not depreciated
Minimum | Equipment
Property, Plant and Equipment [Line Items]
Property and Equipment, Estimated Useful Life	5 years
Maximum | Equipment
Property, Plant and Equipment [Line Items]
Property and Equipment, Estimated Useful Life	8 years

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 4,176	$ 4,092
Work in progress	1,870	3,166
Finished goods	26,584	21,529
Total inventories	$ 32,630	$ 28,787

Property And Equipment, Net - S

Property And Equipment, Net - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Abstract]
Land	$ 1,117	$ 1,132
Equipment	6,724	6,236
Furniture and fixtures	578	640
Computer hardware	3,142	2,118
Leasehold improvements	2,792	1,380
Construction in process	14,758	3,826
Property and equipment, gross	29,111	15,332
Less: accumulated depreciation	(5,958)	(3,885)
Property and equipment, net	$ 23,153	$ 11,447

Property And Equipment, Net - A

Property And Equipment, Net - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Depreciation Expense	$ 2	$ 1.7	$ 2.1

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net - Goodwill (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill [Line Items]
Beginning Balance	$ 37,495	$ 37,795
Effect of currency translation adjustment		(300)
Goodwill acquired	1,018
Ending Balance	38,513	37,495
Global Supply Chain Platform
Goodwill [Line Items]
Beginning Balance	26,233	26,510
Effect of currency translation adjustment	(64)	(277)
Ending Balance	26,169	26,233
Oncology Innovation Platform
Goodwill [Line Items]
Beginning Balance	11,262	11,285
Effect of currency translation adjustment	64	(23)
Goodwill acquired	1,018
Ending Balance	$ 12,344	$ 11,262

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Summary of Identifiable Intangible Asset, Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Accumulated Amortization	$ 6,382	$ 4,260
Finite-lived intangible asset, Net	8,218
Intangible asset, Effect of currency translation adjustment	(424)	(390)
Intangible assets Cost/Fair Value	15,074	15,406
Intangible assets Impairments	170	298
Intangible assets, net	8,522	10,848
CDE In- Process Research and Development
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost/Fair Value	728	1,026
Indefinite-lived intangible asset, Impairments		298
Indefinite-lived intangible asset, Net	728	728
Licenses
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	8,935	8,935
Finite-lived intangible asset, Accumulated Amortization	3,561	2,060
Finite-lived intangible asset, Net	5,374	6,875
Polymed Customer List
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	1,593	1,593
Finite-lived intangible asset, Accumulated Amortization	1,164	938
Finite-lived intangible asset, Net	429	655
Polymed Technology
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	3,712	3,712
Finite-lived intangible asset, Accumulated Amortization	1,297	999
Finite-lived intangible asset, Net	2,415	2,713
Product Rights
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	530	530
Finite-lived intangible asset, Accumulated Amortization	360	263
Finite-lived intangible asset, Impairments	$ 170
Finite-lived intangible asset, Net		$ 267

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets, Net - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments	$ 170	$ 298
Weighted-average useful life of intangible assets	7 years 8 months 12 days
Amortization expense of intangible assets	$ 1,900	1,600	$ 1,600
Research and Development Expenses
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments	200	$ 300	$ 100
Licensing Agreements | Hanmi Pharmaceuticals Co. Ltd.
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 400
Acquired finite-lived intangible assets, amortization period	12 years 9 months
Licensing Agreements | Gland Pharma Ltd
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 4,500
Acquired finite-lived intangible assets, amortization period	5 years
Licensing Agreements | MAIA Pharmaceuticals, Inc
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired	$ 4,000
Acquired finite-lived intangible assets, amortization period	7 years
Customer List | APS
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period	7 years
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period	6 years
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period	12 years

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets, Net - Schedule of Expected Amortization Expense of Finite-Lived Intangible Assets (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2020	$ 2,138
2021	1,782
2022	1,011
2023	982
2024	941
Thereafter	1,364
Finite-lived intangible asset, Net	$ 8,218

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets, Level 1 to Level 2 transfers	$ 0	$ 0	$ 0
Fair value assets, Level 2 to Level 1 transfers	0	0	0
Fair value liabilities, Level 1 to Level 2 transfers	0	0	0
Fair value liabilities, Level 2 to Level 1 transfers	0	0	0
Fair value assets, transfers into Level 3	0	0	0
Fair value assets, transfers out of Level 3	0	0	0
Fair value liabilities, transfers into Level 3	0	0	0
Fair value liabilities, transfers out of Level 3	$ 0	$ 0	$ 0
Pharma Essentia | OTC | Taiwan | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares owned by company	68,000	68,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets:
Total assets	$ 104,726	$ 63,050
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total assets	5,710	413
Significant Other Observable Inputs (Level 2)
Assets:
Total assets	99,016	62,637
Money Market Funds | Cash and Cash Equivalents
Assets:
Total assets	5,460	25
Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cash and Cash Equivalents
Assets:
Total assets	5,460	25
Short-term Investments - Certificates of Deposits | Short-term Investments
Assets:
Total assets	10,054
Short-term Investments - Certificates of Deposits | Cash and Cash Equivalents
Assets:
Total assets	15,110
Short-term Investments - Certificates of Deposits | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets	10,054
Short-term Investments - Certificates of Deposits | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Assets:
Total assets	15,110
Short-term Investments - Commercial Paper | Short-term Investments
Assets:
Total assets	22,835	36,544
Short-term Investments - Commercial Paper | Cash and Cash Equivalents
Assets:
Total assets	51,017	5,396
Short-term Investments - Commercial Paper | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets	22,835	36,544
Short-term Investments - Commercial Paper | Significant Other Observable Inputs (Level 2) | Cash and Cash Equivalents
Assets:
Total assets	51,017	5,396
Available-for-Sale Investment | Short-term Investments
Assets:
Total assets	250	388
Available-for-Sale Investment | Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments
Assets:
Total assets	$ 250	388
Short-term Investments - Corporate Notes | Short-term Investments
Assets:
Total assets		16,699
Short-term Investments - Corporate Notes | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets		16,699
Short-term investments - U.S. Government Bonds | Short-term Investments
Assets:
Total assets		3,998
Short-term investments - U.S. Government Bonds | Significant Other Observable Inputs (Level 2) | Short-term Investments
Assets:
Total assets		$ 3,998

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 27, 2019	Jun. 29, 2018	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Acquisition [Line Items]
Goodwill			$ 38,513				$ 37,495				$ 38,513	$ 37,495	$ 37,795
Contingent equity consideration											748
Research and development licensing fee satisfied with stock												31,545	6,250
Research and development expenses			21,823	$ 19,588	$ 18,507	$ 24,475	$ 20,828	$ 51,202	$ 26,572	$ 21,303	84,393	119,905	$ 76,797
Axis Therapeutics Limited
Acquisition [Line Items]
Capital contributions to joint venture		$ 30,000	30,000								$ 30,000
Percentage of ownership in joint venture		55.00%									55.00%
Axis Therapeutics Limited | Research and Development Expenses
Acquisition [Line Items]
Research and development expenses												$ 24,500
Sponsor investigation charges											$ 1,200
Axis Therapeutics Limited | Licensing Agreements
Acquisition [Line Items]
Research and development licensing fee satisfied with stock, shares		267,952
Research and development licensing fee satisfied with stock		$ 5,000
Axis Therapeutics Limited | XLifeSc | IPR & D
Acquisition [Line Items]
Percentage of ownership in joint venture		45.00%
Percentage of nonmonetary exchange of shares											45.00%
Fair value of equity shares issued			$ 24,500								$ 24,500
Common Stock
Acquisition [Line Items]
Research and development licensing fee satisfied with stock, shares												375,133	568,182
Research and development licensing fee satisfied with stock													$ 1
CIDAL Limited
Acquisition [Line Items]
Asset purchase agreement closing date	Oct. 31, 2019
Cash received	$ 900
Liabilities assumed	1,100
Goodwill	1,000
Contingent equity consideration	800
CIDAL Limited | Maximum
Acquisition [Line Items]
Property and equipment	$ 100
CIDAL Limited | Common Stock
Acquisition [Line Items]
Business acquisition and milestone payments aggregate share consideration	67,796

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expensest (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities Current [Abstract]
Accrued wages and benefits	$ 7,541	$ 5,061
Accrued clinical expenses	2,510	2,653
Accrued operating expenses	1,885	8,128
Deferred revenue	218	190
Accrued R&D licensing fees	384	4,827
Accrued inventory purchases	7,194
Accrued tax withholdings	187
Accrued selling fees and rebates	1,577	423
Accrued construction costs	22,811	16,436
Total accrued expenses	$ 44,307	$ 37,718

Accrued Expenses - Additional I

Accrued Expenses - Additional Information (Detail) - Dunkirk, NY - Manufacturing Facility $ in Millions	12 Months Ended
	Dec. 31, 2019USD ($)
Accrued Liabilities [Line Items]
Accrued construction costs to be funded	$ 22.6
Accrued construction costs received	7.8
Prepaid Expenses and Other Current Assets
Accrued Liabilities [Line Items]
Accrued construction costs to be funded	$ 14.8

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	Jan. 01, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax [Line Items]
U.S. corporate income tax rate	21.00%	21.00%	21.00%	34.00%
Reduce of income tax expense from continuing operations		$ 34,100,000
Valuation allowance for deferred tax assets increase (decrease)		32,300,000	$ 28,100,000
Income tax expense		928,000	100,000	$ 85,000
Federal net operating losses		340,700,000
State net operating losses		74,200,000
Foreign net operating losses		28,500,000
Uncertain tax positions		0	0	0
Amounts recognized for interest and penalties related to unrecognized tax benefits		0	$ 0	$ 0
Federal
Income Tax [Line Items]
Federal net operating losses, subject to expiration		$ 184,800,000
Federal net operating losses, beginning expiration period		2027
Federal net operating losses, not subject to expiration		$ 155,900,000
Maximum
Income Tax [Line Items]
U.S. corporate income tax rate				35.00%

Income Taxes - Components of Lo

Income Taxes - Components of Loss Before Income Tax Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]
Domestic	$ (109,769)	$ (95,479)	$ (125,770)
Foreign	(14,836)	(33,132)	(5,541)
Loss before income tax expense	$ (124,605)	$ (128,611)	$ (131,311)

Income Taxes - Components of th

Income Taxes - Components of the Income Tax Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Current:
Federal			$ 64
State	$ 23	$ 27	(92)
Foreign	419	455	440
Total	442	482	412
Deferred:
Federal	(26,878)	(26,260)	(3,222)
State	(2,567)	(293)	5,799
Foreign	(2,411)	(1,863)	(874)
Total	(31,856)	(28,416)	1,703
Change in valuation allowance	32,342	28,034	(2,030)
Total	$ 928	$ 100	$ 85

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense Differs From the Federal Statutory Rate (Detail)	Jan. 01, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent [Abstract]
Statutory rate	21.00%	21.00%	21.00%	34.00%
State taxes, net of federal benefit		2.00%	0.20%	(4.30%)
Foreign rate differential		0.10%	(0.30%)	(0.60%)
Federal income tax rate change				(0.259)
Valuation allowance		(25.90%)	(21.60%)	1.50%
Other		2.10%	0.60%	(4.80%)
Effective rate		(0.70%)	(0.10%)	(0.10%)

Income Taxes - Schedule of Net

Income Taxes - Schedule of Net Deferred Income Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Components of Deferred Tax Assets and Liabilities [Abstract]
Intangible assets	$ 11,348	$ 10,273
Property and equipment	77	238
Stock-based compensation	9,551	7,508
Net operating loss carryforwards	81,630	60,362
Tax credit carryforwards	9,191	5,341
Research and development deduction	1,493
Reserves and accruals	8,377	6,141
Gross deferred income tax assets	121,667	89,863
Less: valuation allowance	(120,805)	(88,455)
Net deferred income tax assets	862	1,408
Intangible assets	(862)	(922)
Gross deferred income tax liabilities	$ (862)	(922)
Net deferred income tax assets		$ 486

Debt and Lease Obligations - Su

Debt and Lease Obligations - Summary of Balances of Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Current portion of mortgage	$ 686	$ 779
Current portion of finance and capital lease obligations	194	182
Current portion of operating lease obligations	3,010
Long-term portion of finance and capital lease obligations	227	422
Long-term portion of operating lease obligations	7,620
Total	63,876	46,764
Chongqing Maliu Credit Agreement
Debt Instrument [Line Items]
Chongqing Maliu credit agreement	5,731
Senior Secured Loan
Debt Instrument [Line Items]
Senior secured loan, net of debt discount and financing fees of $3,592 and $4,619, respectively	$ 46,408	$ 45,381

Debt and Lease Obligations - _2

Debt and Lease Obligations - Summary of Balances of Debt (Parenthetical) (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Senior Secured Loan
Debt Instrument [Line Items]
Debt discount and financing fees	$ 3,592	$ 4,619

Debt and Lease Obligations - Ad

Debt and Lease Obligations - Additional Information (Detail) $ in Thousands, ¥ in Millions	3 Months Ended		12 Months Ended
	Jun. 30, 2019CNY (¥)	Mar. 31, 2019USD ($)	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
Mortgage payment extended date			Dec. 31, 2020
Chongqing Maliu Riverside Development and Investment Co., LTD (“CQ”)
Debt Instrument [Line Items]
Line of credit facility percentage of periodic payment year one	20.00%
Line of credit facility percentage of periodic payment year two	30.00%
Line of credit frequency of payments			The Company is required to repay the principal amount with accrued interest within three years after the plant receives the U.S. Current Good Manufacturing Practices (“cGMP”) certification, with 20% of the total loan with accrued interest is due within the first twelve months following receiving the certification, 30% of the total loan with accrued interest due within twenty-four months, and the remaining balance with accrued interest due within thirty-six months.
Line of credit due			$ 5,731
China | Chongqing Maliu Riverside Development and Investment Co., LTD (“CQ”)
Debt Instrument [Line Items]
Long-term line of credit	¥ 50		7,200
Long-term line of credit, interest rate	4.75%
Unsecured, Subordinated Bank Loan from China Merchants Bank | China
Debt Instrument [Line Items]
Convertible bonds, aggregate principal value		$ 700
Debt maturity date		Dec. 11, 2019
Interest rate		5.70%
Senior Secured Loan
Debt Instrument [Line Items]
Convertible bonds, aggregate principal value			$ 50,000
Debt maturity date			Jun. 30, 2023
Senior Secured Loan | LIBOR
Debt Instrument [Line Items]
Debt variable rate basis floor			2.00%
Basis spread on variable rate			9.00%

Debt and Lease Obligations - _3

Debt and Lease Obligations - Summary of Components of Lease Expense (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Debt And Lease Obligations [Abstract]
Operating lease cost	$ 3,162
Finance lease cost:
Amortization of assets	81
Interest on lease liabilities	31
Total net lease cost	$ 3,274

Debt and Lease Obligations - Sc

Debt and Lease Obligations - Schedule of Supplemental Balance Sheet Information Related to Leases of Debt (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Finance leases:
Property and equipment, at cost	$ 688
Accumulated amortization, net	(109)
Property and equipment, net	$ 579
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	us-gaap:PropertyPlantAndEquipmentNet
Current obligations of finance leases	$ 194
Long-term portion of finance leases	227
Total finance lease obligations	$ 421
Weighted average remaining lease term (in years):
Operating leases	5 years 2 months 15 days
Finance leases	2 years 1 month 9 days
Weighted average discount rate:
Operating leases	12.90%
Finance leases	5.90%

Debt and Lease Obligations - _4

Debt and Lease Obligations - Schedule of Supplemental Cash Flow Information Related to Leases (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Cash paid for amount included in the measurements of lease liabilities:
Operating cash flows from operating leases	$ 3,374
Operating cash flows from finance leases	31
Financing cash flows from finance leases	183
ROU assets recognized in exchange for new operating lease obligations	$ 1,305

Debt and Lease Obligations - _5

Debt and Lease Obligations - Schedule of Future Minimum Payments and Maturities of Leases (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019
Operating Leases
2020	$ 3,229
2021	2,843
2022	2,623
2023	2,096
2024	2,002
Thereafter	1,950
Total lease payments	14,743
Less: Imputed interest	(4,113)
Total lease obligations	10,630	$ 11,900
Less: Current obligations	(3,010)
Long-term lease obligations	7,620
Finance Leases
2020	214
2021	214
2022	21
Total lease payments	449
Less: Imputed interest	(28)
Total finance lease obligations	421
Less: Current obligations	(194)
Long-term lease obligations	$ 227

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	1 Months Ended		3 Months Ended	12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018Agreement	Mar. 31, 2017USD ($)RelatedParty	Dec. 31, 2019USD ($)Executiveshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares	Jun. 30, 2017shares
Related Party Transaction [Line Items]
Percentage of outstanding common stock holding			5.00%
Convertible Bonds
Related Party Transaction [Line Items]
Amounts owed to related party			$ 4,000,000
Number of related parties received convertible bonds | RelatedParty			2
Amount purchased in convertible bonds by holders of outstanding common stock and a director			$ 2,000,000
Bonds converted into shares of common stock | shares							2,727,273
Nuwagen Limited
Related Party Transaction [Line Items]
Percentage of ownership in joint venture	10.00%
Common Stock
Related Party Transaction [Line Items]
Sale of common stock, shares | shares				14,006,575	7,486,261	6,900,000
Avalon BioMedical
Related Party Transaction [Line Items]
Common stock shares held by related parties | shares				786,061	786,061
Percentage of common stock issued shares				1.00%	1.00%
Avalon BioMedical | Nuwagen Limited
Related Party Transaction [Line Items]
Percentage of ownership interest	90.00%
Avalon BioMedical | In-licensing Agreement
Related Party Transaction [Line Items]
Number of in-licensing agreements | Agreement		2
Payment of upfront fees					$ 5,500,000
Payment of upfront fees in cash					3,500,000
Payment of upfront fees in equity					$ 2,000,000
Avalon BioMedical | In-licensing Agreement | Common Stock
Related Party Transaction [Line Items]
Sale of common stock, shares | shares					107,181
Common stock share price | $ / shares					$ 18.66
Avalon BioMedical | In-licensing Agreement | Research and Development Expenses
Related Party Transaction [Line Items]
Milestone fee paid				$ 1,000,000
Pharma Essentia
Related Party Transaction [Line Items]
Licenses revenue					$ 2,300,000	$ 500,000
Funds paid to related party				$ 400,000
Executive Officer
Related Party Transaction [Line Items]
Number of executives | Executive				1
ZenRx
Related Party Transaction [Line Items]
Licenses revenue				$ 0	0	0
ZenRx | Clinical Development Services
Related Party Transaction [Line Items]
Payments to related party for services received				2,700,000	300,000	600,000
RSJ Consulting LLC | Consulting Services
Related Party Transaction [Line Items]
Payments to related party for services received				$ 0	$ 0	$ 100,000

Business and Economic Collabo_2

Business and Economic Collaborative Agreements - Additional Information (Detail)	Sep. 04, 2017USD ($)ft²	May 01, 2015USD ($)	Oct. 31, 2015USD ($)ft²¥ / SquareMeter	Dec. 31, 2019USD ($)¥ / SquareMeter
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Lease term			10 years
Renewal lease term			10 years
Payment of monthly rent per square meter | ¥ / SquareMeter			5
GMP API Manufacturing Plant
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Minimum capital requirement			$ 30,000,000
Contributed registration capital to subsidiary set up				$ 9,500,000
Grant Disbursement Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Area of building to be built under agreement | ft²	320,000
Area of building space built under agreement | ft²	409,000
Purchase rate of equipment per year in first 10 year term	$ 1			1
Purchase rate of equipment per year in second 10 year term	1			1
Operating expenses committed to spent in first 10 year term	1,520,000,000			1,520,000,000
Operating expenses committed to spent in second 10 year term	$ 1,500,000,000			$ 1,500,000,000
Lease term	10 years			10 years
Renewal lease term	10 years			10 years
Payment of monthly rent per square meter | ¥ / SquareMeter				5
Grant Disbursement Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Construction costs	$ 208,000,000			$ 208,000,000
New York State
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from state		$ 25,000,000
Sublease term		10 years
Sublease, option to extend		With an option to extend the term for an additional 10 years.
Sublease, option to extend term		10 years
Finance sublease, existence of option to extend [true false]		true
New York State | Grant Disbursement Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from state	8,000,000
New York State | Grant Disbursement Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from state	$ 208,000,000
China | GMP API Manufacturing Plant
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Area of building to be built under agreement | ft²			440,000
China | GMP Pharmaceutical Manufacturing Plant
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Area of building to be built under agreement | ft²			510,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	May 23, 2019	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jun. 14, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 9,885	$ 11,011	$ 14,591
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		7,887	9,786	8,031
Unrecognized compensation cost related to non-vested stock options expected to be recognized		$ 14,900
Unrecognized compensation expense related to non-vested stock options, weighted-average period of recognition		1 year 8 months 12 days
Total intrinsic value of stock options exercised		$ 2,700	6,700
Stock options granted, contractual term		10 years
Stock Grants to Officers and Employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 1,100
Shares granted to employees		92,723
Restricted Stock Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 566	1,008	2,160
Unrecognized compensation expense related to non-vested stock options, weighted-average period of recognition		6 months
Shares granted to employees		131,000
Unrecognized cost related to non-vested restricted stock awards		$ 1,500
Maximum | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, vesting period		4 years
Maximum | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance					1,000,000
Minimum | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, vesting period		2 years
2017, 2013, 2007 and 2004 Plans | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock options authorized grant		16,000,000
2017 Omnibus Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase in stock available for issuance under plan	500,000
2017 Plans | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance		1,000,000
Stock-based compensation expense		$ 300	$ 200	$ 0
Percentage of discount on purchase price of common stock		15.00%
Employee stock purchase plan, description		Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from December 1, 2019 to May 31, 2020. The Company expects to offer six-month offering periods after the current period.
Shares of common stock issued		60,825	41,733

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Stock Options
Stock Options, Outstanding Beginning Balance	10,687,650
Stock Options, Granted	875,000
Stock Options, Exercised	(331,779)
Stock Options, Forfeited	(165,488)
Stock Options, Expired	(148,447)
Stock Options, Outstanding Ending Balance	10,916,936	10,687,650
Stock Options, Vested and exercisable	8,292,953
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 8.51
Weighted Average Exercise Price, Granted	13.14
Weighted Average Exercise Price, Exercised	5.86
Weighted Average Exercise Price, Forfeited	13.95
Weighted Average Exercise Price, Expired	8.51
Weighted Average Exercise Price, Outstanding Ending Balance	8.88	$ 8.51
Weighted Average Exercise Price, Vested and exercisable	$ 7.19
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term, Outstanding	5 years 8 months 4 days	6 years 10 months 13 days
Weighted Average Remaining Contractual Term, Vested and exercisable	4 years 10 months 24 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding	$ 69,785	$ 44,688
Aggregate Intrinsic Value, Vested and exercisable	$ 67,012

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Weighted-Average Assumptions Used as Inputs to Black-Scholes Option Pricing Model (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant date fair value	$ 8.06	$ 9.80	$ 7.01
Expected dividend yield	0.00%	0.00%	0.00%
Expected stock price volatility	64.00%	59.00%	66.00%
Risk-free interest rate	2.60%	2.61%	1.74%
Expected life of options (in years)	6 years 3 months 18 days	6 years 1 month 6 days	6 years 2 months 12 days

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock-Based Compensation Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 9,885	$ 11,011	$ 14,591
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	7,887	9,786	8,031
Restricted Stock Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	566	1,008	2,160
Stock Awarded to Directors and Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	1,105		4,400
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	327	217
Cost of Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	248	228	137
Research and Development Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	3,251	2,621	2,030
Selling, General, and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 6,386	$ 8,162	$ 12,424

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders - Schedule Weighted Average Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive common shares	10,860,216	10,593,344	9,928,066
Stock Options and Other Common Stock Equivalents
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive common shares	10,814,635	10,480,084	9,534,658
Unvested Restricted Common Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive common shares	45,581	113,260	393,408

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Schedule of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 128,769	$ 90,722	$ 34,669
Unrealized gain (loss) on investment	(97)	15	(26)
Ending balance	175,855	128,769	90,722
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(656)	(146)	(1,304)
Foreign currency translation adjustment	118	(525)	1,184
Unrealized gain (loss) on investment	(97)	15	(26)
Ending balance	$ (635)	$ (656)	$ (146)

Business Segment, Geographic,_3

Business Segment, Geographic, and Concentration Risk Information - Additional Information (Detail)	6 Months Ended	12 Months Ended
	Dec. 31, 2020ft²	Dec. 31, 2019Segment
Segment Reporting Information [Line Items]
Number of operating segments		3
Number of reportable segments		3
Scenario Forecast
Segment Reporting Information [Line Items]
Number of square foot facility expected to commence operations | ft²	440,000
Segments Deriving Revenue
Segment Reporting Information [Line Items]
Number of reportable segments		2

Business Segment, Geographic,_4

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Segments (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total revenue:
Total consolidated revenue	$ 34,361	$ 19,364	$ 22,197	$ 25,307	$ 21,271	$ 18,428	$ 11,565	$ 37,836	$ 101,229	$ 89,100	$ 38,043
Operating Segments
Total revenue:
Total consolidated revenue									104,959	94,476	47,056
Operating Segments | Oncology Innovation Platform
Total revenue:
Total consolidated revenue									20,562	32,776	1,411
Operating Segments | Global Supply Chain Platform
Total revenue:
Total consolidated revenue									33,970	31,274	28,427
Operating Segments | Commercial Platform
Total revenue:
Total consolidated revenue									50,427	30,426	17,218
Intersegment Eliminations
Total revenue:
Total consolidated revenue									$ (3,730)	$ (5,376)	$ (9,013)

Business Segment, Geographic,_5

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Product Group (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total revenue by product group:
Total consolidated revenue	$ 101,229	$ 89,100	$ 38,043
API Sales
Total revenue by product group:
Total consolidated revenue	12,733	17,952	15,351
Medical Device Sales
Total revenue by product group:
Total consolidated revenue		2,344	1,747
Contract Manufacturing Revenue
Total revenue by product group:
Total consolidated revenue	391	458	1,360
Commercial Product Sales
Total revenue by product group:
Total consolidated revenue	67,411	35,640	17,648
License Fees
Total revenue by product group:
Total consolidated revenue	20,100	32,000	750
Consulting
Total revenue by product group:
Total consolidated revenue	396	387	355
Grant Revenue
Total revenue by product group:
Total consolidated revenue	$ 198	$ 319	$ 832

Business Segment, Geographic,_6

Business Segment, Geographic, and Concentration Risk Information - Summary of Segment Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (123,749)	$ (117,440)	$ (131,170)
Oncology Innovation Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(100,919)	(89,912)	(108,563)
Global Supply Chain Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(8,575)	(16,858)	(7,179)
Commercial Platform
Net loss attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (14,255)	$ (10,670)	$ (15,428)

Business Segment, Geographic,_7

Business Segment, Geographic, and Concentration Risk Information - Summary of Depreciation, Amortization and Assets by Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total depreciation and amortization
Total consolidated depreciation and amortization	$ 3,817	$ 3,269	$ 3,673
Total assets:
Total assets	309,932	231,095
Oncology Innovation Platform
Total depreciation and amortization
Total consolidated depreciation and amortization	762	690	482
Total assets:
Total assets	194,183	135,878
Global Supply Chain Platform
Total depreciation and amortization
Total consolidated depreciation and amortization	1,489	1,603	2,272
Total assets:
Total assets	63,598	58,816
Commercial Platform
Total depreciation and amortization
Total consolidated depreciation and amortization	1,566	976	$ 919
Total assets:
Total assets	$ 52,151	$ 36,401

Business Segment, Geographic,_8

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Geographical Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Total revenue:
Total consolidated revenue	$ 101,229	$ 89,100	$ 38,043
United States
Total revenue:
Total consolidated revenue	67,794	37,904	19,933
India
Total revenue:
Total consolidated revenue	3,066	3,457	8,479
Austria
Total revenue:
Total consolidated revenue	4,422	9,569	3,962
China
Total revenue:
Total consolidated revenue	2,105	4,416	2,803
Spain
Total revenue:
Total consolidated revenue	20,000	30,000
Taiwan
Total revenue:
Total consolidated revenue			500
United Kingdom
Total revenue:
Total consolidated revenue	1,023
Other Foreign Countries
Total revenue:
Total consolidated revenue	$ 2,819	$ 3,754	$ 2,366

Business Segment, Geographic,_9

Business Segment, Geographic, and Concentration Risk Information - Summary of Property and Equipment by Geographical Segment (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Total property and equipment, net:
Total property and equipment, net	$ 23,153	$ 11,447
United States
Total property and equipment, net:
Total property and equipment, net	11,486	6,549
China
Total property and equipment, net:
Total property and equipment, net	$ 11,667	$ 4,898

Business Segment, Geographic_10

Business Segment, Geographic, and Concentration Risk Information - Summary of Customer Revenue and Accounts Receivable Concentration (Detail) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Customer Revenue | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	20.00%	34.00%
Customer Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	16.00%	12.00%	15.00%
Customer Revenue | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	15.00%	9.00%	6.00%
Customer Revenue | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage	14.00%	9.00%	7.00%
Customer Revenue | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage	4.00%	4.00%	19.00%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	45.00%	18.00%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	31.00%	16.00%
Accounts Receivable | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%
Accounts Receivable | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage		12.00%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	$ 34,361	$ 19,364	$ 22,197	$ 25,307	$ 21,271	$ 18,428	$ 11,565	$ 37,836	$ 101,229	$ 89,100	$ 38,043
Revenue recognition cash discount percentage	2.30%								2.30%
Provision for chargebacks and other deductions included as reduction of accounts receivable total	$ 14,394				13,101				$ 14,394	13,101
Deferred revenue	218				190				218	190
Commercial Platform
Revenue Recognition Milestone Method [Line Items]
Provision for chargebacks and other deductions included as reduction of accounts receivable total	14,393				13,101				14,393	13,101
Chargebacks and other revenue deductions expense									87,200	36,500	10,600
Global Supply Chain Platform
Revenue Recognition Milestone Method [Line Items]
Provision for chargebacks and other deductions included as reduction of accounts receivable total	1								1
Revenue to be recognized upon satisfaction of performance obligation	200								200
Global Supply Chain Platform | Out-license Revenue
Revenue Recognition Milestone Method [Line Items]
Deferred revenue	$ 200				$ 200				200	200
Transferred at a Point in Time
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue									$ 100	$ 30,000
Type of Revenue [Extensible List]									atnx:LicenseForIntellectualPropertyMember	atnx:LicenseForIntellectualPropertyMember
Revenue recognized on behalf of milestone event									$ 20,000	$ 2,000
Transferred at a Point in Time | Commercial Platform
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue									50,427	30,426	17,218
Transferred at a Point in Time | Global Supply Chain Platform
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue									$ 30,240	$ 25,898	$ 19,414

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disaggregation Of Revenue [Line Items]
Total revenue	$ 34,361	$ 19,364	$ 22,197	$ 25,307	$ 21,271	$ 18,428	$ 11,565	$ 37,836	$ 101,229	$ 89,100	$ 38,043
Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									100	30,000
Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									20,562	32,776	1,411
Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									30,240	25,898	19,414
Commercial Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									50,427	30,426	17,218
United States
Disaggregation Of Revenue [Line Items]
Total revenue									67,794	37,904	19,933
United States | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									17,367	7,478	2,715
United States | Commercial Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									50,427	30,426	17,218
Spain
Disaggregation Of Revenue [Line Items]
Total revenue									20,000	30,000
Spain | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									20,000	30,000
India
Disaggregation Of Revenue [Line Items]
Total revenue									3,066	3,457	8,479
India | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									3,066	3,457	8,479
Austria
Disaggregation Of Revenue [Line Items]
Total revenue									4,422	9,569	3,962
Austria | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									4,422	9,569	3,962
China
Disaggregation Of Revenue [Line Items]
Total revenue									2,105	4,416	2,803
China | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									562	2,776	911
China | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									1,543	1,640	1,892
United Kingdom
Disaggregation Of Revenue [Line Items]
Total revenue									1,023
United Kingdom | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									1,023
Other Foreign Countries
Disaggregation Of Revenue [Line Items]
Total revenue									2,819	3,754	2,366
Other Foreign Countries | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue									$ 2,819	$ 3,754	2,366
Taiwan
Disaggregation Of Revenue [Line Items]
Total revenue											500
Taiwan | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue											$ 500

Revenue Recognition - Summary o

Revenue Recognition - Summary of Receivables and Contract Liabilities From Contracts with Customers (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Change In Contract With Customer Liability [Abstract]
Accounts receivable, gross	$ 31,207	$ 26,061
Chargebacks and other deductions	(14,394)	(13,101)
Allowance for doubtful accounts	(124)	(9)
Accounts receivable, net	16,689	12,951
Deferred revenue	218	190
Total contract liabilities	$ 218	$ 190

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Accounts Receivable Balances by Reportable Segments (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accounts Receivable By Reportable Segments [Line Items]
Accounts receivable, gross	$ 31,207	$ 26,061
Chargebacks and other deductions	(14,394)	(13,101)
Allowance for doubtful accounts	(124)	(9)
Accounts receivable, net	16,689	12,951
Oncology Innovation Platform
Accounts Receivable By Reportable Segments [Line Items]
Accounts receivable, gross	49
Accounts receivable, net	49
Global Supply Chain Platform
Accounts Receivable By Reportable Segments [Line Items]
Accounts receivable, gross	1,522	7,814
Chargebacks and other deductions	(1)
Allowance for doubtful accounts	(114)	(9)
Accounts receivable, net	1,407	7,805
Commercial Platform
Accounts Receivable By Reportable Segments [Line Items]
Accounts receivable, gross	29,636	18,247
Chargebacks and other deductions	(14,393)	(13,101)
Allowance for doubtful accounts	(10)
Accounts receivable, net	$ 15,233	$ 5,146

Selected Quarterly Financial _3

Selected Quarterly Financial Data (Unaudited) - Schedule of Quarterly Results of Operations (Unaudited) (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Total revenue	$ 34,361	$ 19,364	$ 22,197	$ 25,307	$ 21,271	$ 18,428	$ 11,565	$ 37,836	$ 101,229	$ 89,100	$ 38,043
Costs and operating expenses:
Costs of sales	15,704	17,071	16,942	19,902	14,271	11,965	9,443	11,326	69,619	47,005	25,122
Research and development expenses	21,823	19,588	18,507	24,475	20,828	51,202	26,572	21,303	84,393	119,905	76,797
Selling, general, and administrative expenses	18,109	16,283	17,169	15,188	11,618	11,493	12,817	13,080	66,749	49,008	46,112
Total costs and operating expenses	55,636	52,942	52,618	59,565	46,717	74,660	48,832	45,709	220,761	215,918	148,031
Operating loss	(21,275)	(33,578)	(30,421)	(34,258)	(25,446)	(56,232)	(37,267)	(7,873)	(119,532)	(126,818)	(109,988)
Net loss	(22,411)	(34,787)	(32,105)	(36,230)	(27,162)	(57,260)	(36,950)	(7,339)	(125,533)	(128,711)	(131,396)
Less: net loss attributable to non-controlling interests	(684)	(29)	(74)	(997)	(49)	(11,090)	(91)	(41)	(1,784)	(11,271)	(226)
Net loss attributable to Athenex, Inc.	$ (21,727)	$ (34,758)	$ (32,031)	$ (35,233)	$ (27,113)	$ (46,170)	$ (36,859)	$ (7,298)	$ (123,749)	$ (117,440)	$ (131,170)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted	$ (0.28)	$ (0.45)	$ (0.44)	$ (0.53)	$ (0.41)	$ (0.70)	$ (0.58)	$ (0.12)	$ (1.67)	$ (1.82)	$ (2.63)
Product Sales, Net
Revenue:
Total revenue	$ 14,102	$ 19,237	$ 22,033	$ 25,163	$ 19,009	$ 13,309	$ 11,471	$ 12,605	$ 80,535	$ 56,394	$ 36,106
License and Other Revenue
Revenue:
Total revenue	$ 20,259	$ 127	$ 164	$ 144	$ 2,262	$ 5,119	$ 94	$ 25,231	$ 20,694	$ 32,706	$ 1,937

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Sep. 04, 2017USD ($)	Nov. 30, 2019	Oct. 31, 2015¥ / SquareMeter	Jul. 31, 2015USD ($)	Dec. 31, 2019USD ($)¥ / SquareMeter	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Oct. 31, 2016USD ($)
Deferred rent liability						$ 1,700,000
Rent expense					$ 1,000,000	1,000,000	$ 1,000,000
Lease facilities rental agreement duration			10 years
Lease expiration terms					expire at various times through 2026
Lease term			10 years
Renewal lease term			10 years
Payment of monthly rent per square meter | ¥ / SquareMeter			5
Grant Disbursement Agreement
Lease facilities rental agreement duration	10 years				10 years
Purchase rate of equipment per year in first 10 year term	$ 1				$ 1
Purchase rate of equipment per year in second 10 year term	1				1
Operating expenses committed to spent in first 10 year term	1,520,000,000				1,520,000,000
Operating expenses committed to spent in second 10 year term	$ 1,500,000,000				$ 1,500,000,000
Lease term	10 years				10 years
Renewal lease term	10 years				10 years
Lessee, operating lease, option to extend					option to extend the lease for an additional 10-year term
Lessee, operating lease, existence of option to extend [true false]					true
Payment of monthly rent per square meter | ¥ / SquareMeter					5
China
Rent expense					$ 600,000	600,000	600,000
Commercial Platform
Deferred rent liability						300,000
Rent expense					300,000	300,000	200,000
Irrevocable letter of credit issued								$ 300,000
Maximum | Grant Disbursement Agreement
Construction costs	$ 208,000,000				208,000,000
CDE
Rent expense					$ 300,000	$ 400,000	$ 400,000
Lease facilities rental agreement duration				3 years
Agreement expiration date		2022-11		2019-11
Lease term				3 years
CDE | Maximum
Monthly rental payment				$ 100,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Payments Under Non-Cancelable Leases (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Commitments And Contingencies Disclosure [Abstract]
2020	$ 3,229
2021	2,843
2022	2,623
2023	2,096
2024	2,002
Thereafter	1,950
Total lease payments	$ 14,743

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Allowance for doubtful accounts
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		$ 9	$ 84	$ 155
Charged to Costs & Expenses	[1]	488	28	662
Deductions	[1]	(373)	(103)	(733)
Balance at End of Period		124	9	84
Allowance for chargebacks and other deductions
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		13,101	3,711
Charged to Costs & Expenses	[2]	95,100	36,102	3,834
Deductions	[2]	(93,807)	(26,712)	(123)
Balance at End of Period		14,394	13,101	3,711
Deferred tax asset valuation allowance
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		88,455	60,379	62,308
Charged to Other Accounts	[3]	32,350	28,076	(1,929)
Balance at End of Period		$ 120,805	$ 88,455	$ 60,379
[1]	Increases in the allowance for doubtful accounts consist of our provision for bad debts, which is included within selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss. Decreases in the allowances for doubtful accounts consist of the write-off of specific accounts and the recovery of previously reserved receivables.
[2]	Increases in the allowance for chargebacks and other deductions consist of our provision for chargebacks, cash discounts, returns, fees, and other credits, which are a deduction from product sales on the consolidated statements of operations and comprehensive loss. Decreases in the allowances for chargebacks and other deduction consist of the collection of the underlying accounts and advances received on chargebacks.
[3]	Increases and decreases in the valuation allowance for deferred income tax assets offset the increases and decreases in our gross deferred tax assets, based on the expected realization of those future tax benefits.